Protease 3 (PR3) chimeric autoantibody receptor t cells and related methods and uses
By chimeric autoantibodies (CAAR) binding domain, transmembrane region and signaling region, specific recognition and killing of anti-PR3 antibodies is achieved, solving the difficulty in effectively targeting and killing AAV-related B cells in the prior art. The problem significantly improves the treatment effect.
Patent Information
- Application Number
- CN202380034456.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-21
- Publication Date
- 2024-11-26
AI Technical Summary
Existing methods for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are difficult to effectively target and kill disease-causing B cells, resulting in poor treatment effects.
A chimeric autoantibody receptor (CAAR) has been developed, including extracellular protease 3 (PR3) antibody binding domain, transmembrane region and intracellular signaling region, which can be used by anti-PR3 anti-neutrophil cytoplasmic antibodies Specifically binds and activates T cells through the signaling region, specifically killing B cells expressing anti-PR3 antibodies.
CAAR can efficiently kill cell targets expressing anti-PR3 antibodies, significantly reducing the number of PR3-reactive B cells, thereby effectively treating AAV.
Smart Images

Figure CN119031931A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 312,809, filed on February 22, 2022, entitled “Protease 3 (PR3) Chimeric Autoantibody Receptor T Cells and Related Methods and Uses,” the contents of which are incorporated by reference in their entirety. Incorporation by Reference into the Sequence Listing
[0002] This application is submitted with a sequence listing in electronic format. The sequence listing is provided as a file named 735042022040SeqList.xml created on February 18, 2023, which is 304,200 bytes in size. The information in the electronic sequence listing is incorporated by reference in its entirety. Technical Field
[0003] The present disclosure provides a cell or protein therapeutic agent comprising a proteinase 3 (PR3) antibody binding domain, such as a wild-type PR3 or mutant PR3 protein. The present disclosure also provides a chimeric autoantibody receptor (CAAR) comprising an extracellular PR3 antibody binding domain. The CAAR provided by the present disclosure includes such a CAAR, wherein the extracellular PR3 antibody binding domain is a wild-type or mutant PR3 protein or a fragment thereof that can be specifically bound by an anti-PR3 anti-neutrophil cytoplasmic antibody (ANCA). The present disclosure also provides polynucleotides encoding the provided CAAR, genetically engineered cells such as T cells containing the provided CAAR, and related methods and their use in adoptive cell therapy. Background Art
[0004] Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a rare autoimmune disease characterized by inflammation and small blood vessel damage. Neutrophil serine protease proteinase 3 (PR3), found in the primary granules of neutrophils, is the main autoantigen in AAV. Autoantibodies (ANCA) against PR3 produced by autoreactive B cells are crucial in the development of AAV by activating primed neutrophils that damage blood vessels. Improved methods are needed to target and kill disease-causing B cells. Embodiments that meet such needs are provided. Summary of the invention
[0005] Provided herein is a chimeric autoantibody receptor (CAAR) comprising: (a) an extracellular proteinase 3 (PR3) antibody binding domain; (b) a transmembrane region; and (c) an intracellular signaling region. In some embodiments, the CAAR further comprises a spacer between the extracellular PR3 antibody binding domain and the transmembrane domain. In some embodiments of any embodiment, the PR3 antibody binding domain is from a human PR3 protein or a mutant thereof. In some embodiments of any embodiment, the PR3 antibody binding domain is a mature PR3 protein. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence that exhibits at least 90% sequence identity with SEQ ID NO: 1. In some embodiments of any embodiment, the PR3 antibody binding domain is a wild-type human PR3. In some embodiments of any embodiment, the PR3 antibody binding domain is shown in SEQ ID NO: 1.
[0006] In some embodiments of any embodiment, the PR3 antibody binding domain is a mutant PR3 protein comprising an amino acid substitution at a position selected from the group consisting of G4, H44, D91, D175, and S176 with reference to the position shown in SEQ ID NO: 1. In some embodiments, the amino acid substitution is selected from the group consisting of G4P, H44A, D91N, D175N, S176A, and S176C, or is a conservative substitution thereof. In some embodiments, the amino acid substitution is selected from the group consisting of G4P, H44A, D91N, D175N, S176A, and S176C. In some embodiments, the amino acid substitution is a conservative amino acid substitution selected from the group consisting of G4P, H44A, D91N, D175N, S176A, and S176C.
[0007] In some embodiments of any of the embodiments, the PR3 antibody binding domain is a mutant PR3 protein having reduced enzymatic activity compared to a wild-type PR3 protein (eg, a PR3 protein set forth in SEQ ID NO: 1).
[0008] Embodiments provided include chimeric autoantibody receptors (CAARs) comprising: (a) an extracellular proteinase 3 (PR3) antibody binding domain, wherein the PR3 antibody binding domain is a mutant PR3 protein having reduced enzymatic activity compared to a wild-type PR3 protein having a sequence shown in SEQ ID NO: 1; (b) a transmembrane region; and (c) an intracellular signaling region.
[0009] In some embodiments, the mutant PR3 protein comprises an amino acid substitution in or near the catalytic triad. In some embodiments, the amino acid substitution is in an active site residue selected from the group consisting of: H44, D91, and S176 with reference to the numbering shown in SEQ ID NO: 1. In some embodiments, the amino acid substitution is selected from the group consisting of H44A, D91N, S176A, and S176C. In some embodiments of any of the embodiments, the mutant PR3 protein comprises an amino acid substitution at position H44 with reference to the position numbering in SEQ ID NO: 1.
[0010] In some embodiments, the mutant PR3 protein comprises an amino acid substitution at a position that interferes with the formation of a substrate binding pocket. In some embodiments, the position is G4. In some embodiments of any embodiment, the mutant PR3 protein comprises an amino acid substitution at position G4 with reference to the position number in SEQ ID NO: 1. In some embodiments of any embodiment, the mutant PR3 protein comprises 1, 2, 3, 4 or 5 amino acid substitutions compared to the wild-type PR3 shown in SEQ ID NO: 1. In some embodiments of any embodiment, the mutant PR3 protein comprises a single amino acid substitution compared to SEQ ID NO: 1. In some embodiments of any embodiment, the mutant PR3 protein comprises the amino acid substitution G4P.
[0011] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain; (b) a transmembrane region; and (c) an intracellular signaling region, wherein the PR3 antibody binding domain is a mutant PR3 protein comprising the amino acid substitution G4P. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO:9. In some embodiments, the PR3 antibody binding domain comprises an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO:9. In some embodiments, the PR3 antibody binding domain is shown in SEQ ID NO:9. In some embodiments of any embodiment, the mutant PR3 protein comprises the amino acid substitution H44A.
[0012] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain; (b) a transmembrane region; and (c) an intracellular signaling region, wherein the PR3 antibody binding domain is a mutant PR3 protein comprising the amino acid substitution H44A. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 10. In some embodiments of any embodiment, the PR3 antibody binding domain comprises an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO: 10. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 10. In some embodiments, the amino acid sequence of the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO: 10. In some embodiments of any embodiment, the mutant PR3 protein comprises the amino acid substitution D91N. In some embodiments of any embodiment, the antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO: 4. In some embodiments, the PR3 antibody binding domain is shown in SEQ ID NO: 4.
[0013] In some embodiments of any embodiment, the mutant PR3 protein comprises the amino acid substitution D175N. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO:7 or an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO:7. In some embodiments, the PR3 antibody binding domain is shown in SEQ ID NO:7. In some embodiments of any embodiment, the mutant PR3 protein comprises the amino acid substitution S176A or S176C. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO:2 or an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO:2. In some embodiments of any embodiment, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO:8 or an amino acid sequence exhibiting at least 90% sequence identity with SEQ ID NO:8. In some embodiments, the PR3 antibody binding domain is shown in SEQ ID NO:8.
[0014] In some embodiments of any embodiment, the transmembrane region is or comprises a transmembrane domain from CD4, CD28 or CD8. In some embodiments of any embodiment, the transmembrane region is or comprises a transmembrane domain from CD28. In some embodiments, the transmembrane region comprises human CD28. In some embodiments of any embodiment, the transmembrane region is or comprises SEQ ID NO: 26 or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 26. In some embodiments of any embodiment, the transmembrane region is shown in SEQ ID NO: 26. In some embodiments of any embodiment, the transmembrane region is or comprises a transmembrane domain from CD8a. In some embodiments of any embodiment, the transmembrane domain is human CD8a. In some embodiments of any of the embodiments, the transmembrane region is or comprises SEQ ID NO: 98, or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 98. In some embodiments of any of the embodiments, the transmembrane region is shown in SEQ ID NO: 98.
[0015] In some embodiments of any embodiment, the intracellular signaling region comprises an intracellular signaling domain capable of inducing a primary activation signal in a T cell. In some embodiments, the intracellular signaling domain is a domain from a T cell receptor (TCR) component and / or comprises an immunoreceptor tyrosine activation motif (ITAM). In some embodiments of any embodiment, the intracellular signaling domain is a cytoplasmic signaling domain of a CD3-ζ (CD3ζ) chain. In some embodiments, the intracellular signaling domain is a human CD3ζ chain. In some embodiments of any embodiment, the intracellular signaling domain comprises a sequence as shown in SEQ ID NO: 28, or an amino acid sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 28. In some embodiments of any embodiment, the intracellular signaling domain is shown in SEQ ID NO: 28.
[0016] In some embodiments of any embodiment, the intracellular signaling region further comprises a costimulatory signaling region. In some embodiments, the costimulatory signaling region is located between the transmembrane region and the intracellular signaling domain. In some embodiments of any embodiment, the costimulatory signaling region comprises an intracellular signaling domain of a T cell costimulatory molecule or a signaling portion thereof. In some embodiments of any embodiment, the costimulatory signaling region comprises an intracellular signaling domain of CD28, 4-1BB or ICOS. In some embodiments of any embodiment, the costimulatory signaling region comprises an intracellular signaling domain of 4-1BB. In some embodiments, the costimulatory signaling region comprises human 4-1BB. In some embodiments of any embodiment, the costimulatory signaling region comprises a sequence shown in SEQ ID NO: 27, or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 27. In some embodiments of any of the embodiments, the co-stimulatory signaling region is shown in SEQ ID NO:27.
[0017] In some embodiments of any embodiment, the spacer comprises at least a portion of an immunoglobulin or a variant thereof. In some embodiments of any embodiment, the spacer comprises a hinge region of an immunoglobulin or a variant thereof. In some embodiments, the hinge region of an immunoglobulin is an IgG4 hinge region. In some embodiments, the hinge region is a human IgG4 hinge region or a variant thereof. In some embodiments of any embodiment, the spacer comprises a variant IgG4 hinge region containing a substitution of amino acids CPSC to CPPC compared to a wild-type IgG4 hinge region. In some embodiments of any embodiment, the length of the spacer is less than or less than about 15 amino acids. In some embodiments of any embodiment, the length of the spacer is between 12 and 15 amino acids. In some embodiments of any embodiment, the spacer comprises a sequence shown in SEQ ID NO:22 or SEQ ID NO:23. In some embodiments of any embodiment, the spacer is shown in SEQ ID NO:22.
[0018] In some embodiments of any embodiment, the length of the spacer is between 100 and 150 amino acids. In some embodiments, the length of the spacer is between 110 and 130 amino acids. In some embodiments of any embodiment, the spacer comprises a hinge region of an immunoglobulin and a CH3 region of an immunoglobulin. In some embodiments, the spacer comprises an IgG4 hinge region or a variant thereof and an IgG4 CH3 region. In some embodiments of any embodiment, the spacer comprises a sequence shown in SEQ ID NO: 24 or SEQ ID NO: 96. In some embodiments of any embodiment, the spacer is shown in SEQ ID NO: 24.
[0019] In some embodiments of any embodiment, the length of the spacer is between 200 and 250 amino acids. In some embodiments, the length of the spacer is between 220 and 240 amino acids. In some embodiments of any embodiment, the spacer comprises a hinge region of an immunoglobulin, a CH2 region of an immunoglobulin, or a chimeric CH2 region of two different immunoglobulins and a CH3 region of an immunoglobulin. In some embodiments, the spacer comprises an IgG4 hinge region or a variant thereof, a chimeric CH2 region (IgG2 / 4CH2 region) containing a portion of IgG4 CH2 and a portion of IgG2 CH2, and an IgG4 CH3 region. In some embodiments of any embodiment, the spacer comprises a sequence shown in SEQ ID NO: 25 or SEQID NO: 97. In some embodiments of any embodiment, the spacer is shown in SEQ ID NO: 25. In some embodiments of any embodiment, the spacer comprises amino acids GGGGS (SEQ ID NO: 99). In some embodiments of any embodiment, the spacer is shown in SEQ ID NO: 99. In some embodiments of any embodiment, the spacer is shown in SEQ ID NO: 100.
[0020] In some embodiments of any of the embodiments, the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to the sequence set forth in any one of SEQ ID NOs: 29, 30, 31, 38, 39, 40, 53, 54, 55, 56, 57, 58, 104, 110, or 111. In some embodiments, the CAAR comprises the sequence set forth in any one of SEQ ID NOs: 29, 30, 31, 38, 39, 40, 53, 54, 55, 56, 57, 58, 104, 110, or 111. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO: 29, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO: 29. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO: 30, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO: 30. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO:38, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:38. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO:55, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:55. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO:56, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:56. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO:57, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:57. Provided herein is a CAAR comprising the amino acid sequence set forth in SEQ ID NO:58, or an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:58.
[0021] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO: 9; (b) a spacer comprising the sequence set forth in SEQ ID NO: 25; (c) a transmembrane region comprising the sequence set forth in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence set forth in SEQ ID NO: 27; and (e) an intracellular signaling region comprising the sequence set forth in SEQ ID NO: 28. Provided herein is a CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 55, wherein the amino acid sequence comprises a G4P mutation numbered with reference to a position in SEQ ID NO: 1. In some embodiments, the CAAR comprises the amino acid sequence set forth in SEQ ID NO: 55.
[0022] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO: 10; (b) a spacer comprising the sequence set forth in SEQ ID NO: 24; (c) a transmembrane region comprising the sequence set forth in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence set forth in SEQ ID NO: 27; and (e) an intracellular signaling region comprising the sequence set forth in SEQ ID NO: 28. Provided herein is a CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 57, wherein the amino acid sequence comprises a G4P mutation numbered with reference to a position in SEQ ID NO: 1. In some embodiments, the CAAR comprises the amino acid sequence set forth in SEQ ID NO: 57.
[0023] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO: 9; (b) a spacer comprising the sequence set forth in SEQ ID NO: 100; (c) a transmembrane region comprising the sequence set forth in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence set forth in SEQ ID NO: 27; and (e) an intracellular signaling region comprising the sequence set forth in SEQ ID NO: 28. Provided herein is a CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 104, wherein the amino acid sequence comprises a G4P mutation numbered with reference to a position in SEQ ID NO: 1. In some embodiments, the CAAR comprises the amino acid sequence set forth in SEQ ID NO: 104.
[0024] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO: 9; (b) a spacer comprising the sequence set forth in SEQ ID NO: 22; (c) a transmembrane region comprising the sequence set forth in SEQ ID NO: 98; (d) a co-stimulatory signaling region comprising the sequence set forth in SEQ ID NO: 27; and (e) an intracellular signaling region comprising the sequence set forth in SEQ ID NO: 28. Provided herein is a CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 110, wherein the amino acid sequence comprises a G4P mutation numbered with reference to a position in SEQ ID NO: 1. In some embodiments, the CAAR comprises the amino acid sequence set forth in SEQ ID NO: 110.
[0025] Provided herein is a CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO: 10; (b) a spacer comprising the sequence set forth in SEQ ID NO: 100; (c) a transmembrane region comprising the sequence set forth in SEQ ID NO: 98; (d) a co-stimulatory signaling region comprising the sequence set forth in SEQ ID NO: 27; and (e) an intracellular signaling region comprising the sequence set forth in SEQ ID NO: 28. Provided herein is a CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 111 or 119, wherein the amino acid sequence comprises an H44A mutation numbered with reference to a position in SEQ ID NO: 1. In some embodiments, the CAAR comprises the amino acid sequence set forth in SEQ ID NO: 111 or 119.
[0026] In some embodiments of any embodiment, the CAAR can be specifically bound by anti-PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA). In some embodiments of any embodiment, the PR3 antibody binding domain comprises at least 2, 3, 4, 5, 6 or 7 epitopes recognized by anti-PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA). In some embodiments, the epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO: 90), ANCA3 (PGSHFCGG, SEQ ID NO: 91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO: 92), ANCA5 (FLNNYDAE, SEQ ID NO: 93), ANCA6 (PVPHGTQC, SEQ ID NO: 94) and ANCA7 (CFGDSGGP, SEQ ID NO: 95).
[0027] In some embodiments of any embodiment, the CAAR is specific for PR3 reactive B cells. In some embodiments of any embodiment, Td-tomato is knocked into the endogenous Nur77 locus and the Jurkat reporter cells transduced with the CAAR exhibit less than or less than about 25%, less than or less than about 20%, less than or less than about 15%, less than or less than about 10%, less than or less than about 9%, less than or less than about 8%, less than or less than about 7%, less than or less than about 5%, less than or less than about 4%, less than or less than about 3%, less than or less than about 2% or less than or less than about 1% tonic signaling, as measured by the fluorescence of Td-Tomato by flow cytometry, and determined as the total percentage of cells expressing Td-Tomato in the transduced Jurkat reporter cells. In some embodiments of any embodiment, cells transduced with the CAAR show antigen-specific activation after exposure to anti-human PR3 antibodies. In some embodiments of any of the embodiments, the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to the sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110, and 111. In some embodiments of any of the embodiments, the CAAR comprises the sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110, and 111.
[0028] In some embodiments of any embodiment, the CAAR is capable of killing at least 65% of a cell target expressing an anti-PR3 antibody. In some embodiments of any embodiment, the CAAR is capable of killing at least 65% of each of at least three cell targets expressing different anti-PR3 antibodies, wherein each of the at least three different antibodies binds to a different PR3 epitope. In some embodiments of any embodiment, the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to a sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110, and 111. In some embodiments of any embodiment, the CAAR comprises a sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110, and 111.
[0029] In some embodiments of any embodiment, the polynucleotide comprises a nucleic acid encoding the CAAR. In some embodiments, the polynucleotide is optimized by splice site elimination. In some embodiments of any embodiment, the polynucleotide is codon optimized for expression in human cells. In some embodiments of any embodiment, the polynucleotide comprises a nucleic acid sequence that exhibits at least 85% sequence identity to the sequence shown in any one of SEQ ID NO:59, 60, 61, 68, 69, 70, 83, 84, 85, 86, 87, 88, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158 or 159. In some embodiments, the polynucleotide comprises a sequence as set forth in any one of SEQ ID NOs: 59, 60, 61, 68, 69, 70, 83, 84, 85, 86, 87, 88, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, or 159. In some embodiments of any of the embodiments, the polynucleotide comprises a nucleic acid sequence that exhibits at least 90% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 59, 60, 68, 85, 86, 87, 88, 145, 151, or 152. In some embodiments, the polynucleotide comprises a sequence as set forth in any one of SEQ ID NOs: 59, 60, 68, 85, 86, 87, or 88.
[0030] In some embodiments of any embodiment, the vector comprises the polynucleotide. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a retroviral vector (e.g., a lentiviral vector). In some embodiments of any embodiment, the cell comprises the CAAR. In some embodiments of any embodiment, the cell comprises the polynucleotide or the vector. In some embodiments of any embodiment, the cell is a lymphocyte. In some embodiments of any embodiment, the cell is a NK cell or a T cell. In some embodiments of any embodiment, the cell is a T cell, and the T cell is a CD4+ T cell or a CD8+ T cell. In some embodiments of any embodiment, the cell is a primary cell obtained from a subject. In some embodiments of any embodiment, the cell is an induced pluripotent stem cell. In some embodiments of any embodiment, the cell is differentiated from an induced pluripotent stem cell. In some embodiments of any embodiment, the cell is an allogeneic cell. In some embodiments of any embodiment, the cell is engineered to be immune-reduced.
[0031] In some embodiments of any embodiment, the cell exhibits cytotoxic activity to PR3 reactive B cells. In some embodiments, the cytotoxic activity is directed to multiple PR3 reactive B cells, wherein the multiple PR3 reactive B cells are specific to two or more different PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA) epitopes. In some embodiments, the multiple PR3 reactive B cells are specific to at least 2, 3, 4, 5, 6 or 7 different PR3ANCA epitopes. In some embodiments of any embodiment, the multiple PR3 reactive B cells are specific to at least 4 different PR3 ANCA epitopes. In some embodiments of any embodiment, the multiple PR3 reactive B cells are specific to at least 5 different PR3 ANCA epitopes. In some embodiments of any embodiment, the multiple PR3 reactive B cells are specific to at least 6 different PR3 ANCA epitopes. In some embodiments of any of the embodiments, the ANCA epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO:90), ANCA3 (PGSHFCGG, SEQ ID NO:91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO:92), ANCA5 (FLNNYDAE, SEQ ID NO:93), ANCA6 (PVPHGTQC, SEQ ID NO:94) and ANCA7 (CFGDSGGP, SEQ ID NO:95).
[0032] In some embodiments of any embodiment, the composition comprises the cell. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient. In some embodiments of any embodiment, the composition comprises CD4+ and CD8+ T cells. In some embodiments of any embodiment, the ratio of CD4+ to CD8+ T cells is from or about 1:3 to 3:1. In some embodiments, the ratio of CD4+ to CD8+ T cells is or about 1:2 to 2:1. In some embodiments, the ratio of CD4+ to CD8+ is or about 1:1. In some embodiments of any embodiment, greater than or greater than about 90%, greater than or greater than about 95%, or greater than or greater than about 98% of the cells in the composition are CD3+T cells. In some embodiments of any embodiment, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition express the CAAR. In some embodiments of any embodiment, among the plurality of cells expressing the CAAR in the composition, less than or less than about 10%, less than or less than about 9%, less than or less than about 8%, less than or less than about 7%, less than or less than about 5%, less than or less than about 4%, less than or less than about 3%, less than or less than about 2%, or less than or less than about 1% of the cells exhibit tonic signaling and / or antigen-independent activity or signaling. In some embodiments of any embodiment, the method of killing PR3-reactive B cells comprises contacting PR3-reactive B cells with the cells or the composition. In some embodiments, the method is performed in vitro or ex vivo. In some embodiments, the method is performed in a subject.
[0033] In some embodiments of any embodiment, the PR3 reactive B cells comprise a plurality of PR3 reactive B cells, wherein the plurality of PR3 reactive B cells are specific for two or more different PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA) epitopes. In some embodiments, the plurality of PR3 reactive B cells are specific for 2, 3, 4, 5, 6, or 7 different PR3 ANCA epitopes. In some embodiments of any embodiment, the plurality of PR3 reactive B cells are specific for at least 4 different PR3 ANCA epitopes. In some embodiments of any embodiment, the plurality of PR3 reactive B cells are specific for at least 5 different PR3 ANCA epitopes. In some embodiments of any embodiment, the plurality of PR3 reactive B cells are specific for at least 6 different PR3 ANCA epitopes. In some embodiments of any of the embodiments, the ANCA epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO:90), ANCA3 (PGSHFCGG, SEQ ID NO:91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO:92), ANCA5 (FLNNYDAE, SEQ ID NO:93), ANCA6 (PVPHGTQC, SEQ ID NO:94) and ANCA7 (CFGDSGGP, SEQ ID NO:95).
[0034] In some embodiments of any embodiment, in a plurality of PR3 reactive B cells, the method results in killing greater than or greater than about 80%, greater than or greater than about 90%, greater than or greater than about 95% of PR3 reactive B cells. In some embodiments, the PR3 reactive B cells are IgG+. In some embodiments of any embodiment, the method includes administering the cell or the composition to a subject in need of treatment. In some embodiments, the disease or disorder is an autoimmune disorder. In some embodiments of any embodiment, the disease or disorder is anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). In some embodiments, the AAV is PR3-AAV. In some embodiments of any embodiment, the disease or disorder is selected from granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (EGPA). In some embodiments of any embodiment, the subject is positive for PR3-ANCA. In some embodiments of any embodiment, the method includes testing the subject for PR3-ANCA. In some embodiments, the method includes verifying that the subject tests positive for PR3-ANCA.
[0035] In some embodiments of any embodiment, the subject has been treated with a prior therapy (e.g., one or more prior therapies) for AAV. In some embodiments, the subject has failed to achieve remission or has relapsed after being treated with the prior therapy. In some embodiments of any embodiment, the prior therapy includes one or more of glucocorticoids, cyclophosphamide (CYC), rituximab (RTX), plasma exchange, avacopan (Avacopan), methotrexate (MTX), mycophenolate mofetil (MMF), azathioprine (AZA), leflunomide (LEF), belimumab, mepolizumab and omalizumab. In some embodiments, the glucocorticoid is one or more of prednisolone, methylprednisolone, prednisone, and dexamethasone.
[0036] In some embodiments of any embodiment, the prior therapy includes remission induction therapy (e.g., a remission inducing agent). In some embodiments, the remission induction therapy includes one or more of rituximab, cyclophosphamide, and a glucocorticoid. In some embodiments, the glucocorticoid is one or more of prednisolone, methylprednisolone, prednisone, and dexamethasone. In some embodiments, the glucocorticoid is prednisolone.
[0037] In some embodiments of any embodiment, the prior therapy includes remission maintenance therapy. In some embodiments, the remission maintenance therapy includes one or more of rituximab, methotrexate, azathioprine, mycophenolate mofetil, leflunomide, mepolizumab, and omalizumab. In some embodiments of any embodiment, the method for treating a subject with PR3-ANCA vasculitis includes (i) administering remission induction therapy to the subject and (ii) administering the cell or the composition to the subject. In some embodiments, the remission induction therapy includes cyclophosphamide. In some embodiments, cyclophosphamide is administered to the subject before the cell or the composition is administered to the subject. In some embodiments, a course of cyclophosphamide is administered to the subject at least 1 week, 2 weeks, 3 weeks, or 4 weeks before the cell or the composition is administered to the subject. In some embodiments of any embodiment, the remission induction therapy further includes a glucocorticoid. In some embodiments of any embodiment, the glucocorticoid is prednisolone.
[0038] In some embodiments of any embodiment, a method of treating a subject with PR3-ANCA vasculitis comprises (i) administering cyclophosphamide to the subject and (ii) administering the cell or the composition to the subject. In some embodiments of any embodiment, the method comprises administering cyclophosphamide to the subject prior to administering the cell or the composition to the subject. In some embodiments, a course of cyclophosphamide is administered to the subject at least 1 week, 2 weeks, 3 weeks, or 4 weeks prior to administering the cell or the composition to the subject. In some embodiments of any embodiment, the course of cyclophosphamide is administered according to a dosing schedule that has been determined to be sufficient to reduce ANCA titers in patients with PR3-ANCA vasculitis. In some embodiments of any embodiment, cyclophosphamide is administered at an oral dose of 2 mg / kg / day for at least 1 week, 2 weeks, 3 weeks, or 4 weeks prior to administering the cell or the composition to the subject. In some embodiments of any embodiment, cyclophosphamide is administered at an IV dose of 15 mg / kg every 2 weeks for up to 3 doses prior to administering the cell or the composition to the subject. In some embodiments of any of the embodiments, after administering the cell or the composition to the subject, the subject is not treated with cyclophosphamide.
[0039] In some embodiments of any embodiment, the method comprises administering a glucocorticoid to the subject prior to administering the cell or the composition to the subject. In some embodiments of any embodiment, the method comprises administering a glucocorticoid to the subject after administering the cell or the composition to the subject. In some embodiments of any embodiment, the method of treating a subject with PR3-ANCA vasculitis comprises (i) administering a preconditioning therapy to the subject that has been shown to effectively deplete ANCA, and then (ii) administering the cell or the composition to the subject. In some embodiments, the preconditioning therapy comprises cyclophosphamide. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 A schematic diagram of the PR3 CAAR construct is depicted showing components including a signal peptide, an extracellular anti-PR3 antibody binding domain (PR3), a spacer, a transmembrane domain (TM), a co-stimulatory (Co-Stim) domain, and a signaling domain.
[0041] Figure 2Depicted are the differential tonic signaling and activation observed in Nur77-TdTomato reporter Jurkat T cells expressing different PR3-CAARs as described in Example 1 after 24 hours of incubation in the absence of target (PBS control conditions, top row) and in the presence of target α-PR3 (anti-PR3) antibodies (activation conditions, bottom row).
[0042] Figure 3 Depicted are the reported PR3 ANCA epitopes on the PR3 crystal structure (left) and the epitope bins of PR3 reactive antibodies generated by subcutaneous immunization of rodents with native active human PR3 protein compared to reference antibodies (right). Each circle in the group diagram represents an antibody in a paired competition experiment, with the line indicating competition between two antibodies connected by the line. Based on similar blocking characteristics, antibodies are grouped into epitope bins as shown.
[0043] Figure 4 Depict the results of in vitro cytotoxicity assays performed to evaluate the effects of target to effector ratios as described in Example 4, Part A. After IgG+CHO-S target cells were co-cultured with primary T cells expressing one of four PR3CAARs or without CAR (simulated CAAR), killing efficiency was assessed by measuring the loss of live target cells at 24 hours. As a control, the culture of simulated CAR cells (T cells not expressing CAR) and target cells was assessed.
[0044] Figure 5 Depicted is CAAR-T cell potency against targets expressing different anti-PR3 antibodies with various epitope reactivities as described in Example 4, Part B.
[0045] Figure 6 The effect of surface density of anti-PR3 antibodies on PR3-CAAR T cell potency is depicted. IgG was assessed by mean fluorescence intensity (MFI) + -αPR3 antibody expression density on CHO-S target and for each individual IgG + - CHO-S targets evaluated for CAAR T cell killing. Killing efficiencies against high (H) and low (L) density targets as well as combined high and low density targets (pools) are shown.
[0046] Figure 7 Depicted are CAAR T cell activation in the absence of target cells (CAAR alone) and after 24 h of exposure to cellular targets expressing anti-PR3 (L = low density, H = high density, pool = combined low and high density). + Activation was measured by measuring CD69 levels on PR3-CAAR T cells.
[0047] Figure 8 Depicted are the killing efficiency of PR3 CAAR T cells in the presence of soluble anti-PR3 monoclonal antibodies (left panel) or soluble anti-neutrophil cytoplasmic autoantibodies (ANCA) derived from patients with ANCA-associated vasculitis (right panel).
[0048] Fig. 9 A- Fig. 9C Depicted is the targeting of PR3-CAAR T cells to immunization-induced PR3-reactive B cell populations in vivo. Fig. 9 A (left panel) shows that PR3-immunized mice receiving PR3-CAAR T cells show statistically significant depletion of PR3-reactive spleen class-switched B2 cell populations. The upper left FACS dot plot shows the presence of PR3-reactive class-switched B2 cells after treatment with mock CAAR T cells, and the right panel shows the depletion of such cells after treatment with PR3 CAAR T cells. The bottom panel shows that the percentage of PR3-reactive spleen class-switched B2 cells was significantly reduced after treatment with PR3 CAAR T cells compared to control conditions (mock CAAR T cells and no T cells). Fig. 9 B (middle panel) shows that PR3-immunized mice receiving PR3-CAAR T cells displayed statistically significant depletion of PR3-reactive CD19-CD43+ cells in the bone marrow, as indicated by the percentage (top panel) and total counts (bottom panel) of such cells. Fig. 9C (Right) shows that PR3-immunized mice receiving PR3-CAAR T cells displayed statistically significant depletion of PR3-reactive class-switched B2 cells in mesenteric lymph nodes, as indicated by the percentage (top panel) and total counts (bottom panel) of such cells.
[0049] Fig.10 Depicted is the PR3-CAAR T cell response to IgG with a G4S linker 阴性 Minimal off-target killing of hybridomas.
[0050] Fig.11 Depicted are CAAR T cell activation in the absence of target cells (CAR alone) and 24 h after exposure to cellular targets expressing anti-PR3. + Activation was measured by measuring CD69 levels on PR3-CAAR T cells.
[0051] Fig.12 Depicted is the in vivo targeting of PR3-reactive K562 cells by PR3-CAAR T cells in the NSG xenograft model. DETAILED DESCRIPTION
[0052] Provided herein are cells or biological agents (e.g., proteins) therapeutic agents comprising PR3 antibody binding domains (e.g., wild-type PR3 proteins or mutant PR3 proteins). As used herein, the term "PR3 antibody binding domain" is a protein or polypeptide that can be bound by one or more anti-PR3 antibodies (e.g., one or more PR3 ANCAs). The PR3 antibody binding domain can be a wild-type PR3 protein or a mutant PR3 protein, or a part of a wild-type PR3 protein or a mutant PR3 protein. In some embodiments, the PR3 antibody binding domain comprises one or more ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises multiple ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises at least 2, 3, 4, 5, 6, or 7 ANCA epitopes disclosed in Table 1. In some embodiments, the PR3 antibody binding domain comprises multiple (e.g., at least 2, 3, 4, 5, 6, or 7) ANCA epitopes disclosed in Table 1. In some embodiments, the PR3 antibody binding domain is one or more of the PR3 antibody binding domains described in Section IA.
[0053] In certain embodiments, the PR3 antibody binding domain (e.g., mutant PR3 protein) has a mutation (e.g., point mutation) compared to the wild-type PR3 protein. In some embodiments, the mutation of the PR3 antibody binding domain reduces its enzymatic activity (compared to the corresponding binding domain without mutation) and / or the mutation makes the PR3 antibody binding domain inactive. In some embodiments, the corresponding antibody binding domain is a wild-type PR3 protein (e.g., a wild-type PR3 protein with a sequence of SEQ IN NO: 1). The enzymatic activity of the PR3 antibody binding domain can be assessed using the substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (MeAAPV) (MilliporeSigma) according to Silva et al. (2010) J Autoimmunity and Van Der Geld et al. (2002) Clin Exp Immunol. In some embodiments, the proteolysis of the synthetic substrate by the PR3 antibody binding domain is monitored via measuring the absorbance at 405nm that varies over time. In some embodiments, specific activity can be calculated by reference to a standard with p-nitroanilide (cleaved substrate).In certain embodiments, the PR3 antibody binding domain (eg, mutant PR3 protein) comprises one or more epitopes recognized or bound by PR3-ANCA.
[0054] In some embodiments, the biologic (e.g., protein) therapeutic comprises a soluble PR3 antibody binding domain (e.g., a wild-type PR3 protein or a mutant PR3 protein, or a portion of a wild-type PR3 protein or a mutant PR3 protein). In some embodiments, the cell therapeutic comprises a cell and a PR3 antibody binding domain (e.g., a wild-type PR3 protein or a mutant PR3 protein) expressed on the cell surface. In some embodiments, the PR3 antibody binding domain is a portion of a recombinant receptor.
[0055] Also provided herein is a method of treating an autoimmune disease (eg, AAV) comprising administering a cell or protein therapeutic.
[0056] In another aspect, provided herein is a method of depleting antigen-specific immune cells, the method comprising administering a cell or biologic therapeutic (e.g., a protein) comprising a mutant PR3 protein that binds or is capable of binding to at least 1, 2, 3, 4, 5, 6, or 7 epitopes on PR3-specific immune cells (e.g., at least 1, 2, 3, 4, 5, 6, or 7 of the ANCA epitopes disclosed in Table 1). In one embodiment, the therapeutic agent is a cell therapeutic agent. In another embodiment, the therapeutic agent is a protein therapeutic agent.
[0057] The embodiments provided include cell therapeutic agents containing wild-type PR3 proteins or mutant PR3 proteins. In some embodiments, chimeric autoantibody receptors (CAARs) comprising extracellular protease 3 (PR3) antibody binding domains are provided herein. In some embodiments, the extracellular domain of the CAAR provided is composed of a PR3 antibody binding domain. In some embodiments, the PR3 antibody binding domain can be bound by anti-neutrophil cytoplasmic antibodies (ANCA), and is therefore used as a binding target for identification by autoantibodies that cause disease. Autoantibodies expressed on autoreactive cells therefore serve as specific targets for CAAR, and subsequently CAAR can destroy or kill autoreactive cells. Also provided herein is a method for targeting autoantibodies and B cells that produce autoantibodies to CAAR. In some embodiments, such methods include methods of treatment and use for treating diseases or conditions (such as autoimmune diseases or conditions, such as anti-neutrophil cytoplasmic autoantibodies (ANCA) associated vasculitis (AAV)) that are usually caused by ANCA targeting PR3.
[0058] PR3 expressed in granulomatous lesions is an autoantigen target of autoreactive B cells and T cells. Autoantigens can include autoantigens or antigens from normal tissues, which are targets of cell-mediated or antibody-mediated immune responses that can lead to the development of autoimmune diseases. Autoantigen PR3 (neutrophil serine protease proteinase 3) can be combined with anti-neutrophil cytoplasmic antibodies (ANCA), which induce neutrophils to produce superoxide and change their apoptosis. Anti-PR3 autoantibodies (PR3-ANCA) target and bind PR3, and are associated with the development of vasculitis.
[0059] Certain therapeutic interventions for treating such autoantibody-mediated diseases target immune cells, such as B cells, that produce and display autoantibodies on their cell surfaces. The advantage of the method disclosed herein is that it allows targeted killing of immune cells expressing anti-PR3 autoantibodies, such as B cells expressing anti-PR3 autoantibodies. Other immune cells (including other B cells) are not targeted by this method, and therefore, it is expected that they can continue to produce antibodies that protect subjects from infection. In addition, the CAAR provided includes such CAAR, wherein the PR3 antibody binding domain can be recognized by multiple different ANCAs (e.g., 2, 3, 4, 5, 6 or more) to provide a wide range of killing activity for cells expressing different reactive autoantibodies. The CAAR provided also exhibits antibody target-specific killing with low tension (low tension activity, as exemplified herein).
[0060] All publications (including patent documents, scientific articles, and databases) mentioned in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. If the definitions set forth herein are contrary to or otherwise inconsistent with definitions set forth in patents, applications, published applications, and other publications incorporated herein by reference, the definitions set forth herein take precedence over the definitions incorporated herein by reference.
[0061] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. I. PR3 Chimeric Autoantibody Receptor
[0062] In some aspects, a CAAR comprising a PR3 antibody binding domain is provided. Typically, the PR3 antibody binding domain can be specifically bound by an anti-PR3 antibody (e.g., one or more PR3 ANCAs). Polynucleotides encoding PR3 CAARs are also provided. In some embodiments, the polynucleotides provided can be incorporated into DNA or RNA constructs (such as those that can be introduced into cells). Cells expressing PR3 CAARs, compositions containing such cells, and their use in adoptive cell therapy are also provided herein. A. PR3 Antibody Binding Domain
[0063] The CAAR disclosed herein generally comprises an extracellular PR3 antibody binding domain (e.g., a PR3 autoantibody binding domain). The PR3 antibody binding domain can be a wild-type PR3 protein or a fragment or mutant thereof. In certain embodiments, the antibody binding domain comprises a PR3 protein or a fragment or mutant thereof that can be specifically bound by an anti-PR3 anti-neutrophil cytoplasmic antibody (PR3-ANCA). The extracellular antibody binding domain of the CAAR provided comprises one or more epitopes recognized or bound by PR3-ANCA. In some embodiments, the extracellular antibody binding domain is a PR3 autoantigen.
[0064] Serine protease protease 3 (PR3) is an enzyme released during neutrophil inflammation. PR3 is initially transcribed as an inactive precursor (zymogen), and then undergoes two-stage post-translational modifications to become active. First (via signal peptidase), N-terminal signal peptide cleavage is performed, and then the N-terminal front dipeptide is cut by the cysteine protease cathepsin C necessary for enzyme activity. Secondly, the propeptide form undergoes propeptide cleavage at the C-terminus, which is crucial for particle packaging. This forms the final conformation of the catalytic triad of the residues and mature PR3 (Crisford et al., Respiratory Research, Vol. 19, Article No.: 180, 2018). Residues histidine-44, aspartic acid-91 and serine-176 are the triplets constituting the active site of PR3.
[0065] In some embodiments, the PR3 antibody binding domain is a wild-type PR3 protein. In some embodiments, the PR3 protein is a human protein. In some embodiments, the PR3 antibody binding domain is a precursor PR3 protein, such as a PR3 with an N-terminal dipeptide and / or a C-terminal propeptide. In some embodiments, the PR3 antibody binding domain is a mature PR3 protein. The PR3 antibody binding domain can also be a variant of human PR3, such as a mutant or isoform of human PR3, including a precursor or mature PR3 thereof.
[0066] In some embodiments, the PR3 antibody binding domain is an unprocessed precursor PR3 protein at the N-terminus and / or C-terminus. In some embodiments, the precursor PR3 protein does not have catalytic activity. In some embodiments, the PR3 protein contains an N-terminal dipeptide. In some embodiments, the PR3 antibody binding domain comprises the sequence of SEQ ID NO:5. In some embodiments, the PR3 protein contains an N-terminal dipeptide. In some embodiments, the PR3 antibody binding domain comprises the sequence of SEQ ID NO:3. The PR3 antibody binding domain can also be a variant of any of the foregoing items, such as a mutant or isoform of any of the foregoing items. In some embodiments, the PR3 antibody binding domain has a sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO:3 or 5.
[0067] In some embodiments, the PR3 antibody binding domain is a mature wild-type PR3 protein. In some embodiments, the PR3 antibody binding domain comprises the sequence of SEQ ID NO: 1. In some embodiments, the PR3 antibody binding domain is a mature PR3 protein having the sequence of SEQ ID NO: 1. The PR3 antibody binding domain can also be a variant of any of the foregoing items, such as a mutant or isoform of SEQ ID NO: 1. In some embodiments, the PR3 antibody binding domain has a sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 1.
[0068] In some embodiments, the PR3 antibody binding domain is a mutant PR3 protein. In certain embodiments, the PR3 antibody binding domain is a mutant PR3 protein with a mutation (e.g., a point mutation) compared to wild-type PR3 (e.g., compared to the PR3 shown in SEQ ID NO: 1). The point mutation may occur, for example, at a residue corresponding to SEQ ID NO: 1, residues 4, 44, 91, 175, or 176. In some embodiments, the point mutation may be mutated to any other amino acid at the position. In some embodiments, the point mutation is a mutation to any other amino acid except an amino acid with a bulky side chain. In some embodiments, the point mutation is a mutation to alanine (A), valine (V), isoleucine (I), leucine (L), methionine (M), glycine (G), proline (P), cysteine (C), serine (S), threonine (T), asparagine (N), or glutamine (Q). In some embodiments, the amino acid mutation is G4P, H44A, D91N, D175N, S176A, or S176C.
[0069] In some embodiments, the point mutation of PR3 reduces the enzymatic activity of PR3, such as making the antibody binding domain inactive. In some embodiments, compared with wild-type PR3 (e.g., a wild-type PR3 comprising a sequence of SEQ ID NO: 1), the point mutation of PR3 reduces the enzymatic activity of mutant PR3. In some embodiments, compared with the enzymatic activity of wild-type PR3 (e.g., shown in SEQ ID NO: 1), the point mutation of PR3 reduces the enzymatic activity of mutant PR3 by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%. In certain embodiments, the point mutation of PR3 reduces the enzymatic activity of mutant PR3 by at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more. In some embodiments, compared with the enzymatic activity of wild-type PR3 (e.g., shown in SEQ ID NO: 1), the point mutation of PR3 reduces the enzymatic activity by 1% to 11%, 10% to 21%, 20% to 31%, 30% to 41%, 40% to 51%, 50% to 61%, 60% to 71%, 70% to 81%, 80% to 91% or 90% to 100%. In a specific embodiment, compared with the enzymatic activity of wild-type PR3 (e.g., shown in SEQ ID NO: 1), the enzymatic activity is reduced by at least 50%, such as generally reduced by at least 60%, 70%, 80%, 90% or more.
[0070] The PR3 antibody binding domains of CAAR provided herein are recognized and capable of being bound by anti-PR3 antibodies (e.g., PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA)). ANCA is found in the serum of approximately 90% of all active and / or untreated Wegener's granulomatosis (WG) patients, and approximately 90% of all cytoplasmic ANCA WG patients bind to PR3 (Bruner et al. (2010) Clin and Experimental Immunol). In some embodiments, the PR3 antibody binding domains disclosed herein comprise one or more ANCA binding epitopes. In some embodiments, the PR3 antibody binding domain comprises 1, 2, 3, 4, 5, 6 or 7 ANCA epitopes listed in Table 1 below. Table 1: ANCA epitopes on the PR3 antibody binding domain Epitope sequence SEQ ID NO: ANCA1 epitopes MAHRPPSPAL 89 ANCA2 epitopes AQPHSRPYMAS 90 ANCA3 epitopes PGSHFCGG 91 ANCA4 epitope VVLGAHNVRTQ 92 ANCA5 epitopes FLNNYDAE 93 ANCA6 epitopes PVPHGTQC 94 ANCA7 epitope CFGDSGGP 95
[0071] In some embodiments, the PR3 antibody binding domain contains one or more PR3 epitopes capable of being bound by ANCA. Figure 3 Certain ANCA epitopes that may be present on the PR3 antibody binding domains of the provided CAARs are shown. In some embodiments, Figure 3 Any one or more (such as a combination of two or more) of the ANCA epitopes in may be present in the PR3 antibody binding domain of the CAAR provided. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 2. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 3. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 4. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 5. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 6. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 7. In some embodiments, the PR3 antibody binding domain comprises ANCA epitope 1. In some embodiments, the PR3 antibody binding domain comprises a combination of 2 ANCA epitopes, 3 ANCA epitopes, 4 ANCA epitopes, 5 ANCA epitopes, 6 ANCA epitopes, or 7 ANCA epitopes.
[0072] In some embodiments, the PR3 antibody binding domain comprises at least two ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises at least three ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises at least four ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises at least five ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises five ANCA epitopes. In some embodiments, the PR3 antibody binding domain comprises at least six ANCA epitopes. In some aspects of the foregoing embodiments, the ANCA epitope comprises one or more of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some aspects of the foregoing embodiments, the ANCA epitope comprises one or more of SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some aspects of the foregoing embodiments, the ANCA epitope is selected from the group consisting of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some aspects of the foregoing embodiments, the ANCA epitope is selected from the group consisting of SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95.
[0073] In some embodiments, the PR3 antibody binding domain comprises at least two, three, four, five, or six of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some embodiments, the PR3 antibody binding domain comprises in its sequence at least two sequences selected from the epitopes of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some embodiments, the PR3 antibody binding domain comprises in its sequence at least three sequences selected from the epitopes of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some embodiments, the PR3 antibody binding domain comprises in its sequence at least four sequences selected from the group consisting of epitopes of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some embodiments, the PR3 antibody binding domain comprises in its sequence at least five sequences selected from the group consisting of epitopes of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95. In some embodiments, the PR3 antibody binding domain comprises in its sequence a sequence of an epitope as shown in SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, and SEQ ID NO: 95.
[0074] In certain embodiments, the length of the human PR3 antibody binding domain is 231 or fewer amino acids. In certain embodiments, the length of the human PR3 antibody binding domain is 229 or fewer amino acids, 227 or fewer amino acids, 225 or fewer amino acids, 223 or fewer amino acids, 222 or fewer amino acids, 221 or fewer amino acids, 219 or fewer amino acids, or 217 or fewer amino acids. In some embodiments, the length of the PR3 antibody binding domain is 217 to 231 amino acids. In some embodiments, the length of the PR3 antibody binding domain is 217 to 222 amino acids. In some embodiments, the length of the PR3 antibody binding domain is 219 to 231 amino acids. In some embodiments, the length of the PR3 antibody binding domain is 221 to 231 amino acids. In some embodiments, the length of the PR3 antibody binding domain is 221 amino acids.
[0075] In some embodiments, CAAR is specific for PR3 reactive immune cells (e.g., B cells). In some embodiments, "specificity" with respect to binding refers to the binding of a protein (e.g., a ligand) to a cognate binding partner protein present in a sample or expressed on a cell, but the protein does not substantially recognize or bind to other molecules in the sample or expressed on the cell. For example, an extracellular PR3 antibody binding domain is specific for PR3-ANCA expressed on one or more reactive immune cells (e.g., B cells). In some embodiments, the observation that a protein or other binding molecule binds to a specific PR3-ANCA or specifically binds to a PR3-ANCA protein does not necessarily mean that it binds to different PR3-ANCAs that recognize different epitopes.
[0076] In some embodiments, the extent of binding of a PR3 antibody binding domain or a CAAR containing the same to an unrelated, non-PR3-ANCA protein is less than or about 10% of the binding of the PR3 antibody binding domain or CAAR to the target PR3-ANCA as measured by flow cytometry. A variety of assays are known for assessing binding or determining whether a protein (e.g., a ligand) specifically binds to a cognate binding partner (e.g., PR3-ANCA). Suitable assays for measuring the binding of one protein to another include, for example, surface plasmon resonance (SPR) analysis (see, for example, Scatchard et al., Ann. NY Acad. Sci. 51: 660, 1949; Wilson, Science 295: 2103, 2002; Wolff et al., Cancer Res. 53: 2560, 1993; and U.S. Pat. Nos. 5,283,173, 5,468,614 or equivalents), immunoassays (such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA)), or binding assays achieved by monitoring changes in the spectral or optical properties of proteins via fluorescence, ultraviolet absorption, circular dichroism, or nuclear magnetic resonance (NMR). Other exemplary assays include, but are not limited to, Western blots, ELISAs, analytical ultracentrifugation, spectroscopy, flow cytometry, sequencing, and other methods for detecting expressed polynucleotides or protein binding. In particular, binding can be assessed by flow cytometry. 1. Exemplary PR3 Antibody Binding Domains
[0077] PR3 CAARs typically comprise an extracellular antibody binding domain (e.g., an extracellular autoantibody binding domain) that includes, is, or comprises one or more of the PR3 antibody binding domains disclosed herein. In some embodiments of the provided embodiments, the PR3 antibody binding domain is or comprises a sequence as set forth in any one of SEQ ID NOs: 1 to 10, or a sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 1 to 10.
[0078] In some embodiments, the PR3 antibody binding domain is a mature human PR3 antibody binding domain, such as that shown in SEQ ID NO: 1. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO: 1.
[0079] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 176 compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the mutation is S176A. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 2, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 and containing the mutation S176A. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO:2.
[0080] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing an unprocessed C-terminus compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 3, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 3 and containing an unprocessed C-terminus. In some embodiments, the PR3 antibody binding domain consists of the sequence set forth in SEQ ID NO: 3.
[0081] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 91 compared to mature human PR3 (e.g., mature human PR3 as shown in SEQ ID NO: 1). In some embodiments, the mutation is D91N. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 4, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 4 and containing the mutation D91N. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO: 4.
[0082] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing an unprocessed N-terminus compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 5, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 5 and containing an unprocessed N-terminus. In some embodiments, the PR3 antibody binding domain consists of the sequence set forth in SEQ ID NO: 5.
[0083] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at the N-terminus compared to mature human PR3 (e.g., mature human PR3 shown in SEQ ID NO: 1). In some embodiments, the mutation is an N-terminal Ile deletion. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO: 6, or has at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 6 and contains an N-terminal Ile deletion. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO: 6.
[0084] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 175 compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the mutation is D175N. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 7, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 7 and containing the mutation D175N. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO:7.
[0085] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 176 compared to mature human PR3 (e.g., mature human PR3 set forth in SEQ ID NO: 1). In some embodiments, the mutation is S176C. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 8, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity with the amino acid sequence set forth in SEQ ID NO: 8 and containing the mutation S176C. In some embodiments, the PR3 antibody binding domain consists of the sequence set forth in SEQ ID NO: 8.
[0086] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 4 compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the mutation is G4P. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 9, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 9 and containing the mutant G4P. In some embodiments, the PR3 antibody binding domain consists of the sequence set forth in SEQ ID NO: 9.
[0087] In some embodiments, the PR3 antibody binding domain is a mutant PR3 antibody binding domain containing a mutation at position 44 compared to mature human PR3 (e.g., mature human PR3 as set forth in SEQ ID NO: 1). In some embodiments, the mutation is H44A. In some embodiments, the PR3 antibody binding domain comprises the amino acid sequence set forth in SEQ ID NO: 10, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 10 and containing the mutation H44A. In some embodiments, the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO:10.
[0088] In some embodiments of the provided embodiments, the PR3 antibody binding domain is encoded by a sequence as set forth in any one of SEQ ID NOs: 11 to 20, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 11 to 20.
[0089] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 11, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 11. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 11. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 11.
[0090] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 12, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 12. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 12. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 12. In some embodiments, the encoded PR3 antibody binding domain contains the mutation S176A with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0091] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 13, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 13. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 13. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 13.
[0092] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 14, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 14. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 14. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 14. In some embodiments, the encoded PR3 antibody binding domain contains the mutation D91N with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0093] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 15, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 15. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 15. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 15.
[0094] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 16, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 16. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 16. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 16.
[0095] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 17, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 17. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 17. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 17. In some embodiments, the encoded PR3 antibody binding domain contains the mutation D175N with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0096] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 18, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 18. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 18. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 18. In some embodiments, the encoded PR3 antibody binding domain contains the mutation S176C with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0097] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 19, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 19. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 19. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 19. In some embodiments, the encoded PR3 antibody binding domain contains a mutant G4P with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0098] In some embodiments, the PR3 antibody binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 20, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 20. In some embodiments, the PR3 antibody binding domain is encoded by a sequence comprising the sequence set forth in SEQ ID NO: 20. In some embodiments, the PR3 antibody binding domain is encoded by a sequence consisting of the sequence set forth in SEQ ID NO: 20. In some embodiments, the encoded PR3 antibody binding domain contains the mutation H44A with reference to the residue numbering of the mature PR3 set forth in SEQ ID NO: 1.
[0099] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 1. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 11, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 11. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 11. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 11.
[0100] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 2. In some such embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 12, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 12. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 12. In some such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 12.
[0101] In some such embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 3. In some such embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 13, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 13. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 13. In some such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 13.
[0102] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 4. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 14, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 14. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 14. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 14.
[0103] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 5. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 15, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 15. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 15. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 15.
[0104] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 6. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 16, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 16. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 16. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 16.
[0105] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 7. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 17, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 17. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 17. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 17.
[0106] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 8. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 18, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 18. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 18. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 18.
[0107] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 9. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 19, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 19. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 19. In some embodiments, PR3CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 19.
[0108] In some embodiments, the PR3 antibody binding domain is or contains the sequence set forth in SEQ ID NO: 10. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 20, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 20. In some embodiments, the PR3 antibody binding domain is or contains the amino acid sequence encoded by SEQ ID NO: 20. In some such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 20.
[0109] Exemplary PR3 antibody binding domains (or autoantibody binding domains) and corresponding SEQ ID NOs are listed in Table 2 below. Table 2: PR3 antibody binding domains Constructs Mutations compared to WT sequence Amino acid SEQ ID NO: Nucleotide SEQ ID NO: PR3_1 WT (natural) 1 11 PR3_2 S176A 2 12 PR3_3 Unprocessed C-terminus 3 13 PR3_4 D91N 4 14 PR3_5 Unprocessed N-terminus 5 15 PR3_6 N-terminal Ile deletion 6 16 PR3_7 D175N 7 17 PR3_8 S176C 8 18 PR3_9 G4P 9 19 PR3_10 H44A 10 20 B. Spacer
[0110] In some embodiments, the CAAR disclosed herein further comprises a spacer (also referred to as a spacer region in some cases). In some embodiments, the spacer region is located between the extracellular domain comprising or consisting of an antibody binding component or an autoantibody recognition component (e.g., a PR3 antibody binding domain) and a transmembrane domain (also referred to as a transmembrane region herein).
[0111] In some embodiments, the length of the spacer is adjusted to optimize the biophysical synaptic distance between the CAAR expressing cell and the target of the CAAR (e.g., an anti-PR3 antibody, e.g., a PR3 autoantibody). In some embodiments, the CAAR is expressed by a T cell, and the length of the spacer is adjusted to a length compatible with T cell activation or is adjusted to optimize CAAR T cell performance.
[0112] In some embodiments, the spacer is selected such that the CAAR has less than 20% tonic signaling as assessed using the assay described in Example 2. In some embodiments, the tonic signaling is less than 15%, as assessed using the assay described in Example 2. In some embodiments, the tonic signaling is less than 10%, as assessed using the assay described in Example 2. In some embodiments, the spacer is selected such that the CAAR is capable of killing at least 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the cell targets expressing the anti-PR3 antibody. In some embodiments, the CAAR is capable of killing at least 65% of the cell targets expressing the anti-PR3 antibody as assessed using the assay described in Example 3.
[0113] In some embodiments, the spacer can have a length that provides increased cellular responsiveness upon antigen binding compared to the absence of the spacer or compared to an alternative spacer of a different length (e.g., a longer length).
[0114] Exemplary spacers include spacers having a length of at least or at least about 10 to at least or at least about 300 amino acids, at least or at least about 10 to at least or at least about 229 amino acids, at least or at least about 10 to at least or at least about 200 amino acids, at least or at least about 10 to at least or at least about 175 amino acids, at least or at least about 10 to at least or at least about 150 amino acids, at least or at least about 10 to at least or at least about 125 amino acids, at least or at least about 10 to at least or at least about 100 amino acids, at least or at least about 10 to at least or at least about 75 amino acids, at least or at least about 10 to at least or at least about 50 amino acids, at least or at least about 10 to at least or at least about 40 amino acids, at least or at least about 10 to at least or at least about 30 amino acids, at least or at least about 10 to at least or at least about 20 amino acids, or at least or at least about 10 to at least or at least about 15 amino acids, and including any integer between the endpoints of any recited range. Exemplary spacers include spacers having a length of at least or at least about 50 to at least or at least about 175 amino acids, at least or at least about 50 to at least or at least about 150 amino acids, at least or at least about 10 to at least or at least about 125 amino acids, at least or at least about 50 to at least or at least about 100 amino acids, at least or at least about 100 to at least or at least about 300 amino acids, at least or at least about 100 to at least or at least about 250 amino acids, at least or at least about 125 to at least or at least about 250 amino acids, or at least or at least about 200 to at least or at least about 250 amino acids, and including any integer between the endpoints of any listed ranges. In some embodiments, the length of the spacer is at least or at least about 12 amino acids, at least or at least about 119 amino acids, at least or at least about 125 amino acids, at least or at least about 200 amino acids, or at least or at least about 220 amino acids, or at least or at least about 225 amino acids. In some embodiments, the length of the spacer is at least or about 13 amino acids, at least or about 120 amino acids, at least or about 125 amino acids, at least or about 200 amino acids, or at least or about 220 amino acids, or at least or about 229 amino acids. In some embodiments, the length of the spacer is at or about 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 amino acids or less.In some embodiments, the spacer is at least or about 100 amino acids in length, such as at least or about 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 amino acids in length.
[0115] In some embodiments, the length of the spacer is at least or at least about 125 to at least or at least about 300 amino acids, at least or at least about 125 to at least or at least about 250 amino acids, at least or at least about 125 to at least or at least about 230 amino acids, at least or at least about 125 to at least or at least about 200 amino acids, at least or at least about 125 to at least or at least about 180 amino acids, at least or at least about 125 to at least or at least about 150 amino acids, at least or at least about 150 to at least or at least about 300 amino acids, at least or at least about 150 to at least or at least about 250 amino acids, at least or at least about 150 to at least or at least about 230 amino acids, at least or at least about 150 to at least or at least about 200 amino acids, at least or at least about 180 amino acids. At least about 150 to at least or at least about 180 amino acids, at least or at least about 180 to at least or at least about 300 amino acids, at least or at least about 180 to at least or at least about 250 amino acids, at least or at least about 180 to at least or at least about 230 amino acids, at least or at least about 180 to at least or at least about 200 amino acids, at least or at least about 200 to at least or at least about 300 amino acids, at least or at least about 200 to at least or at least about 250 amino acids, at least or at least about 200 to at least or at least about 230 amino acids, at least or at least about 230 to at least or at least about 300 amino acids, at least or at least about 230 to at least or at least about 250 amino acids, or 250 to at least or at least about 300 amino acids in length. In some embodiments, the length of the spacer is at least or at least about 129, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, or 230 amino acids, or a length between any of the foregoing values.
[0116] In some embodiments, the spacer can be or include at least a portion of an immunoglobulin constant region or a variant or modified form thereof, such as a hinge region. In some embodiments, the constant region or portion is of human IgG (such as IgG4, IgG2, or IgG1). In some embodiments, the portion of an immunoglobulin constant region includes a hinge region (e.g., an IgG4 hinge region) and optionally one or more additional domains of the constant region (such as a C H 1 / C L , C H 2 and / or C H 3 and / or Fc region). In some aspects, the portion of the constant region acts as a spacer between the autoantibody recognition component (e.g., PR3 antibody binding domain) and the transmembrane domain.
[0117] Exemplary spacers include IgG hinge alone, H 2 and C H One or more of the IgG hinges in the 3 domains or in conjunction with the C H In some embodiments, the spacer comprises a separate IgG hinge. In some embodiments, the IgG hinge, C H 2 and / or C H 3 may be derived in whole or in part from IgG4 or IgG2, such as derived in whole or in part from human IgG4 or human IgG2. In some embodiments, the spacer may be a hinge, C H 2 and / or C H 3 sequences. In some embodiments, the hinge region comprises all or a portion of an IgG4 hinge region. In some embodiments, the hinge region comprises all or a portion of an IgG4 hinge region and / or an IgG2 hinge region, wherein the IgG4 hinge region is optionally a human IgG4 hinge region, and the IgG2 hinge region is optionally a human IgG2 hinge region; C H Region 2 contains IgG4 C H Region 2 and / or IgG2 C H All or part of region 2, in which IgG4 C H Region 2 is optionally human IgG4 C H Region 2, and IgG2 C H Region 2 is optionally human IgG2 C H Zone 2; and / or C H Region 3 contains IgG4 C H Region 3 and / or IgG2C H All or part of region 3, of which IgG4 C H Region 3 is optionally human IgG4 C HRegion 3, and IgG2 C H Region 3 is optionally human IgG2 C H Region 3. In some embodiments, hinge C H 2 and C H 3 contains the hinge region C from IgG4 H 2 and C H In some embodiments, the hinge region is chimeric and comprises hinge regions from human IgG4 and human IgG2; H Region 2 is chimeric and contains C from human IgG4 and human IgG2. H Zone 2; and / or said C H Region 3 is chimeric and contains C from human IgG4 and human IgG2. H In some embodiments, the spacer comprises an IgG4 / 2 chimeric hinge or a modified IgG4 hinge containing at least one amino acid substitution compared to the human IgG4 hinge region; a human IgG2 / 4 chimeric C H Region 2; and human IgG4 C H Zone 3.
[0118] In some embodiments, the spacer may contain one or more single amino acid mutations in one or more domains of the immunoglobulin, such as in one or more domains of the hinge, CH2 or CH3 region. In some examples, the amino acid modification is a substitution of serine (S) with proline (P) in the hinge region of IgG4. In some embodiments, the spacer is or contains an IgG4 hinge, which is a variant IgG4 hinge region comprising a substitution of amino acids CPSC to CPPC compared to a wild-type IgG4 hinge region. In some embodiments, the spacer contains CH2 of IgG4 as a variant CH2, wherein the amino acid modification is a substitution of asparagine (N) with glutamine (Q) to reduce glycosylation heterogeneity, such as C of the full-length IgG4 Fc sequence shown in SEQ ID NO: 132. H N177Q mutation at position 177 in region 2, or C of the full-length IgG2 Fc sequence shown in SEQ ID NO: 133 H N176Q at position 176 in zone 2.
[0119] In some instances, the length of the spacer is at or about 12 amino acids or is no more than or is no more than about 12 amino acids in length. In some instances, the length of the spacer is at or about 15 amino acids or is no more than or is no more than about 15 amino acids in length.
[0120] In some embodiments, the spacer comprises all or part of an immunoglobulin hinge or a modified form thereof or consists of them. In some embodiments, the length of the spacer is or is about 15 amino acids or less. In some embodiments, the spacer comprises all or part of an immunoglobulin hinge, optionally an IgG4 hinge or a modified form thereof, or consists of them, and / or comprises about 15 or less amino acids. In some embodiments, the length of the spacer is or is about 13 amino acids, and / or comprises all or part of an immunoglobulin hinge, optionally IgG4 or a modified form thereof, or consists of them. In some embodiments, the length of the spacer is or is about 12 amino acids, and / or comprises all or part of an immunoglobulin hinge, optionally IgG4 or a modified form thereof, or consists of them. In some embodiments, the spacer comprises the formula X1PPX2P (SEQ ID NO: 124), wherein X1 is glycine, cysteine or arginine, and X2 is cysteine or threonine. In some embodiments, the spacer does not comprise a CD28 extracellular region or a CD8 extracellular region. In some cases, the spacer has a methionine residue at the C-terminus. In some embodiments, the spacer comprises or consists of a sequence of SEQ ID NO: 22, 23, 125, 126, 127, 128, 129, 130, or 131, or a variant of any of the foregoing items having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains the sequence shown in SEQ ID NO: 22. In some embodiments, the spacer is or contains the sequence shown in SEQ ID NO: 23.
[0121] In some embodiments, the spacer is or comprises a C sequence that is identical to, for example, a human immunoglobulin (such as IgG4 and / or IgG2). HIn some aspects, the length of the spacer is or is about 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124 or 125 amino acids, or the length is between any of the aforementioned values. In some aspects, the length of the spacer is or is about 119 or 120 amino acids. In some embodiments, the spacer comprises or consists of the following: SEQ ID NO: 24 or 96 sequence, or a variant of any of the preceding items having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence that is at least or about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 24 or 96. In some embodiments, the spacer is or contains the sequence set forth in SEQ ID NO: 24. In some embodiments, the spacer is or contains the sequence set forth in SEQ ID NO: 96. In some embodiments, the spacer is or contains the sequence set forth in SEQ ID NO: 96. In some embodiments, the length of the spacer is or is about 120 amino acids.
[0122] In some embodiments, the spacer may be derived in whole or in part from IgG4 and / or IgG2 and may contain mutations, such as one or more single amino acid mutations in one or more domains. In some examples, the amino acid modification is a substitution of serine (S) with proline (P) in the hinge region of IgG4. In some embodiments, the spacer is or contains an IgG4 hinge, which is a variant IgG4 hinge region comprising a substitution of amino acids CPSC to CPPC compared to a wild-type IgG4 hinge region. In some embodiments, the amino acid modification is a substitution of asparagine (N) with glutamine (Q) to reduce glycosylation heterogeneity, such as C of the full-length IgG4 Fc sequence shown in SEQ ID NO: 132. H N177Q mutation at position 177 in region 2, or C of the full-length IgG2 Fc sequence shown in SEQ ID NO: 133 H N176Q at position 176 in zone 2.
[0123] In some embodiments, the spacer is or comprises an IgG4 / 2 chimeric hinge or a modified IgG4 hinge; an IgG2 / 4 chimeric C H Region 2; and IgG4 C H3 regions, and optionally having a length of about 228 or 229 amino acids; or a spacer set forth in SEQ ID NO: 25 or 97. In some embodiments, the spacer is or contains an amino acid sequence that is at least or about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 25 or 97. In some embodiments, the spacer is or contains a sequence set forth in SEQ ID NO: 25 or 97.
[0124] Other exemplary spacers include, but are not limited to, those described in the following documents: Hudecek et al. (2013) Clin. Cancer Res., 19: 3153; Hudecek et al. (2015) Cancer Immunol. Res., 3 (2): 125-135, or WO 2014031687. In some embodiments, the nucleotide sequence of the spacer is optimized to reduce RNA heterogeneity after expression. In some embodiments, the nucleotide sequence of the spacer is optimized to reduce hidden splicing sites or reduce the possibility of splicing events occurring at the splicing sites.
[0125] In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:23. In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:22. In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:96. In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:24. In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:97. In some embodiments, the spacer comprises or consists of the amino acid sequence shown in SEQ ID NO:25.
[0126] In some embodiments, the spacer comprises or consists of an amino acid sequence that exhibits at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 23, 96 or 97. In some such embodiments, the spacer is encoded by a polynucleotide that has been optionally optimized for codon usage and / or reduced RNA heterogeneity. In some embodiments, the spacer comprises or consists of an amino acid sequence that exhibits at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 22, 24 or 25. In some such embodiments, the spacer is encoded by a polynucleotide that has been optionally optimized for codon usage and / or reduced RNA heterogeneity.
[0127] In some embodiments, the CAAR comprises a hinge domain derived from a CD8 polypeptide. In some embodiments, the spacer comprises or consists of a sequence of SEQ ID NO: 101, or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence having at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence having at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto. In some embodiments, the spacer is or contains a sequence set forth in SEQ ID NO: 101.
[0128] In some embodiments, the amino acid sequence of the spacer comprises or consists of (GGGGS)n. In some such embodiments, the spacer has between 5 and 30 amino acids. In some embodiments, n is between 1 and 6 (inclusive). In one embodiment, n=1 (SEQ ID NO:99). In another embodiment, n=2. In another embodiment, n=3 (SEQ ID NO:100).
[0129] In some embodiments, the spacer comprises or consists of the sequence of SEQ ID NO: 99, or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence having at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the spacer is or contains the sequence set forth in SEQ ID NO: 99.
[0130] In some embodiments, the spacer comprises or consists of a sequence of SEQ ID NO: 100, or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence having at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto. In some embodiments, the spacer is or contains a sequence of SEQ ID NO: 100.
[0131] In some embodiments, the spacer is a flexible linker spacer.In some embodiments, the amino acid sequence of the spacer comprises or consists of EAAAK (SEQ ID NO: 102).
[0132] In some embodiments, the spacer comprises or consists of the sequence of SEQ ID NO: 102, or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In some embodiments, the spacer is or contains an amino acid sequence having at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the spacer is or contains the sequence set forth in SEQ ID NO: 102. C. Transmembrane domain
[0133] In some embodiments, the extracellular binding domain containing the PR3 antibody binding component is connected to one or more intracellular signaling components (e.g., a signaling component that simulates activation by a TCR complex) through a transmembrane domain (also referred to herein as a transmembrane region). Therefore, in some embodiments, the PR3 antibody binding domain and the spacer are connected to one or more transmembrane domains (such as those described herein) and an intracellular signaling domain (such as those described herein) containing one or more intracellular components. In some embodiments, the transmembrane domain is fused to the extracellular domain. In one embodiment, a transmembrane domain that naturally associates with one of the domains in the receptor is used. In some cases, the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
[0134] In some embodiments, the membrane-spanning domain is derived from a natural or synthetic source. When the source is natural, in some aspects, the domain is derived from any membrane-bound protein or a membrane-spanning protein. The membrane-spanning domain includes those derived from the following (i.e., at least one or more membrane-spanning domains comprising the following): α, β or ζ chains of T cell receptors, CD3ε, CD4, CD5, CD8, CD9, CD16, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137 and / or CD154. For example, the membrane-spanning domain can be a CD28 membrane-spanning domain comprising the amino acid sequence shown in SEQ ID NO:26 or 134. In some embodiments, the transmembrane domain of the receptor is the transmembrane domain of human CD28 (e.g., the 27 amino acid transmembrane domain or the 28 amino acid sequence of human CD28 (Accession No.: P10747.1)) or a variant thereof, or a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 26 or 134, or an amino acid sequence that exhibits at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 26 or 134. In some embodiments, the transmembrane domain of the receptor is the transmembrane domain of human C8a (e.g., a 21 amino acid transmembrane domain or a 22 amino acid sequence of human CD8a (Accession No.: P01732)) or a variant thereof, or a transmembrane domain comprising the amino acid sequence shown in SEQ ID NO: 98 or 135, or an amino acid sequence that exhibits at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 98 or 135.
[0135] In some embodiments, the transmembrane domain is encoded by a polynucleotide that has been optionally optimized for codon usage and / or reduced RNA heterogeneity (e.g., by removing cryptic splice sites). In some cases, the transmembrane domain has a methionine residue at the N-terminus.
[0136] In some embodiments, the transmembrane domain is or contains SEQ ID NO: 26 or 134, or an amino acid sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 26 or 134. In some embodiments, the transmembrane domain is or contains the sequence set forth in SEQ ID NO: 26 or 134. In some embodiments, the transmembrane domain is or contains SEQ ID NO: 98 or 135, or an amino acid sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 98 or 135. In some embodiments, the transmembrane domain is or contains the sequence set forth in SEQ ID NO: 98 or 135.
[0137] Alternatively, in some embodiments, the membrane spaning domain is synthetic. In some aspects, the synthetic membrane spaning domain mainly comprises hydrophobic residues, such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of the synthetic membrane spaning domain. In some embodiments, connection is achieved by a joint, a spacer and / or one or more membrane spaning domains. D. Intracellular signaling domain
[0138] CAARs typically include an intracellular signaling domain containing at least one or more intracellular signaling components. The intracellular signaling domain includes those that simulate or imitate the following: a signal through a natural antigen receptor, a signal through a combination of such a receptor and a costimulatory receptor, and / or a signal through a separate costimulatory receptor. In some embodiments, a short oligopeptide or polypeptide linker (e.g., a linker of 2 to 10 amino acids in length, such as a linker containing glycine and serine, such as a glycine-serine doublet) exists and forms a connection between the transmembrane domain of a CAAR and the intracellular signaling domain.
[0139] In some embodiments, CAAR comprises an intracellular component or signaling domain of a TCR complex, such as a TCR CD3 chain that mediates T cell activation and cytotoxicity, such as a CD3 ζ (CD3-ζ) chain. Therefore, in some aspects, the PR3 antibody binding domain is connected to one or more cell signaling modules. In some embodiments, the cell signaling module includes a CD3 intracellular signaling domain and / or other CD transmembrane domains. In some embodiments, CAAR further comprises a portion of one or more additional molecules (such as Fc receptor γ, CD8, CD4, CD25, or CD16).
[0140] In some embodiments, after connecting CAAR, the cytoplasmic domain or intracellular signaling region of CAR stimulates and / or activates at least one of the normal effector functions or responses of immune cells (e.g., engineered to express CAR T cells). For example, in some contexts, CAAR induces the function of T cells, such as cytolytic activity or T helper cell activity, such as the secretion of cytokines or other factors. In some embodiments, a truncated portion of the intracellular signaling domain of an antigen receptor component or a co-stimulatory molecule (e.g., if it transduces an effector function signal) is used instead of a complete immunostimulatory chain. In some embodiments, one or more intracellular signaling domains include a cytoplasmic sequence of a T cell receptor (TCR), and in some aspects also include a co-receptor (which acts in parallel with this receptor in a natural context to initiate signal transduction after antigen receptor engagement) and / or any derivatives or variants of such molecules, and / or any synthetic sequence with the same functional capabilities.
[0141] In the case of natural TCR, full activation generally requires not only signaling via TCR, but also co-stimulatory signals. Therefore, in some embodiments, in order to promote full activation, components for generating secondary or co-stimulatory signals are also included in CAAR. In other embodiments, CAAR does not include components for generating co-stimulatory signals. In some aspects, additional CAARs are expressed in the same cell and provide components for generating secondary or co-stimulatory signals.
[0142] In some aspects, T cell activation is described as being mediated by two categories of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences), and those that act in an antigen-independent manner to provide secondary or co-stimulatory signals (secondary cytoplasmic signaling sequences). In some aspects, a CAAR comprises one or both of such cytoplasmic signaling sequences.
[0143] In some aspects, CAARs include primary cytoplasmic signaling sequences that regulate primary stimulation and / or activation of the TCR complex. Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs (which are called immunoreceptor tyrosine activation motifs or ITAMs). Examples of primary cytoplasmic signaling sequences containing ITAMs include those derived from TCR or CD3ζ, FcRγ, CD3γ, CD3δ, and CD3ε. In some embodiments, the intracellular signaling region in CAAR contains a cytoplasmic signaling domain, a portion thereof, or a sequence derived from CD3ζ. In some embodiments, CD3ζ includes the amino acid sequence shown in SEQ ID NO:28, 136, or 137. In some embodiments, CD3ζ is encoded by a polynucleotide that has been optionally optimized for codon usage and / or reduced RNA heterogeneity (e.g., by removing cryptic splice sites). In some embodiments, the intracellular signaling domain comprises a human CD3 zeta stimulatory signaling domain or a functional variant thereof, such as a 112 AA cytoplasmic domain of isoform 3 of human CD3 zeta (Accession No.: P20963.2) or a CD3 zeta signaling domain as described in U.S. Pat. No. 7,446,190 or U.S. Pat. No. 8,911,993. In some embodiments, the intracellular signaling domain comprises an amino acid sequence as set forth in SEQ ID NO: 28, 136, or 137, or an amino acid sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 28, 136, or 137. In some embodiments, CD3 zeta is or contains the sequence set forth in SEQ ID NO: 28.
[0144] In some embodiments, CAAR comprises a signaling domain (e.g., an intracellular or cytoplasmic signaling domain) and / or a transmembrane portion of a co-stimulatory molecule (e.g., a T cell co-stimulatory molecule). Exemplary co-stimulatory molecules include CD28, 4-1BB, OX40, DAP10, and ICOS. For example, a co-stimulatory molecule may be derived from 4-1BB and may include the amino acid sequence shown in SEQ ID NO:27. In some embodiments, the co-stimulatory molecule from 4-1BB is encoded by a polynucleotide, which has been optionally optimized for codon usage and / or reduction of RNA heterogeneity (e.g., by removing hidden splice sites). In some embodiments, the co-stimulatory molecule from 4-1BB includes the amino acid sequence shown in SEQ ID NO:27. In some embodiments, the intracellular domain comprises an intracellular co-stimulatory signaling domain of 4-1BB or a functional variant or portion thereof, such as a 42 amino acid cytoplasmic domain of human 4-1BB (Accession No. Q07011.1) or a functional variant or portion thereof, such as an amino acid sequence shown in SEQ ID NO: 27, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 27. In some embodiments, the co-stimulatory molecule may be derived from CD28 and may comprise an amino acid sequence shown in SEQ ID NO: 138 encoded by a nucleotide sequence shown in SEQ ID NO: 139. In some embodiments, the intracellular signaling domain comprises an intracellular co-stimulatory signaling domain of human CD28 or a functional variant or portion thereof, such as a 41 amino acid domain thereof, and / or such a domain having a LL to GG substitution at positions 186-187 of the native CD28 protein. In some embodiments, the intracellular signaling domain may comprise an amino acid sequence as set forth in SEQ ID NO: 138 or 140, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 138 or 140. In some aspects, the same CAR comprises both a stimulatory or activation component (e.g., a cytoplasmic signaling sequence) and a co-stimulatory component.
[0145] In some aspects, the transmembrane domain contains the transmembrane portion of CD28. The extracellular domain and the transmembrane domain can be directly or indirectly connected. In some embodiments, the extracellular domain and the transmembrane domain are connected by a spacer (any spacer as described herein). In some embodiments, the chimeric antigen receptor contains the intracellular domain of the T cell costimulatory molecule, such as between the transmembrane domain and the intracellular signaling domain. In some aspects, the T cell costimulatory molecule is CD28 or 4-1BB.
[0146] In some embodiments, the stimulation or activation component is contained in one CAAR, and the costimulatory component is provided by another CAAR that recognizes another antigen. In some embodiments, CAAR includes activation or stimulation CAAR and costimulatory CAAR expressed on the same cell (see WO 2014 / 055668). In some aspects, PR3-CAAR is a stimulation or activation CAAR; in other aspects, it is a costimulatory CAAR. In some embodiments, the cell also includes an inhibitory CAAR (iCAR, see Fedorov et al., Sci. Transl. Medicine, 5 (215) (December 2013)), whereby the stimulation or activation signal delivered by PR3-CAAR is reduced or inhibited by the binding of inhibitory CAAR to its ligand, for example, to reduce off-target effects.
[0147] In some embodiments, the two receptors induce activation and inhibitory signals, respectively, to the cell, such that ligation of one receptor to its antigen activates the cell or induces a response, but ligation of a second inhibitory receptor to its antigen induces a signal that inhibits or attenuates the response. An example is a combination of an activating CAAR and an inhibitory CAAR. For example, this strategy can be used, for example, to reduce the likelihood of off-target effects in a setting where an activating CAAR binds an antigen that is expressed in a disease or disorder but is also expressed on normal cells, and an inhibitory receptor binds a separate antigen that is expressed on normal cells but not on cells of the disease or disorder.
[0148] In some aspects, the chimeric receptor is or includes an inhibitory CAAR, and includes an intracellular component that weakens or inhibits an immune response (e.g., a response promoted by ITAM and / or costimulation in a cell). Examples of such intracellular signaling components are those found on immune checkpoint molecules (including PD-1, CTLA4, LAG3, BTLA, OX2R, TIM-3, TIGIT, LAIR-1, PGE2 receptors, EP2 / 4 adenosine receptors (including A2AR)). In some aspects, the engineered cell includes an inhibitory CAAR, which includes a signaling domain of this inhibitory molecule or a signaling domain derived from this inhibitory molecule, so that it is used to weaken, for example, a cell response induced by activation and / or costimulation CAAR.
[0149] In certain embodiments, the intracellular signaling region comprises a CD28 transmembrane and signaling domain connected to a CD3 (e.g., CD3-ζ) intracellular domain. In some embodiments, the intracellular signaling domain comprises a chimeric CD28 and 4-1BB (CD137; TNFRSF9) co-stimulatory domain connected to a CD3 ζ intracellular domain.
[0150] In some embodiments, CAR encompasses one or more (e.g., two or more) co-stimulatory domains and stimulation or activation domains (e.g., primary activation domains) in the cytoplasmic portion. Exemplary CARs include intracellular components of CD3-ζ and 4-1BB. E. Exemplary CAAR
[0151] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 22; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 26; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:29, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:29. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:32, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:32 and containing the mutation S176A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:35, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:35 and containing an unprocessed C-terminus.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:38, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:38 and containing the mutation D91N. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:41, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:41 and containing an unprocessed N-terminus. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:44, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:44 and containing an N-terminal Ile deletion. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:47, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:47 and containing the mutation D175N.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:50, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:50 and containing the mutation S176C. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:53, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:53 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:56, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:56 and containing the mutation H44A.
[0152] In some embodiments, the antibody binding domain of PR3 CAAR comprises a mutant PR3 antibody binding domain containing a mutation at position 91 compared to mature human PR3. In some embodiments, the mutation of the PR3 antibody binding domain is D91N. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO:4 and a spacer having an amino acid sequence as shown in SEQ ID NO:23. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO:4 and a spacer having an amino acid sequence as shown in SEQ ID NO:22. In some embodiments, PR3 CAAR has an amino acid sequence as shown in SEQ ID NO:38.
[0153] In some embodiments, the antibody binding domain of PR3 CAAR comprises a mutant PR3 antibody binding domain containing a mutation at position 44 compared to mature human PR3. In some embodiments, the mutation of the PR3 antibody binding domain is H44A. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 23. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 22. In some embodiments, PR3 CAAR has an amino acid sequence as shown in SEQ ID NO: 56.
[0154] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 24; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 26; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:30, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:30. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:33, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:33 and containing the mutation S176A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:36, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:36 and containing an unprocessed C-terminus.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:39, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:39 and containing the mutation D91N. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:42, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:42 and containing an unprocessed N-terminus. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:45, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:45 and containing an N-terminal Ile deletion. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:48, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:48 and containing the mutation D175N.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:51, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:51 and containing the mutation S176C. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:54, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:54 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:57, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:57 and containing the mutation H44A.
[0155] In some embodiments, the antibody binding domain of PR3 CAAR comprises a mutant PR3 antibody binding domain containing a mutation at position 44 compared to mature human PR3. In some embodiments, the mutation of the PR3 antibody binding domain is H44A. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 96. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 24. In some embodiments, PR3 CAAR has an amino acid sequence as shown in SEQ ID NO: 57.
[0156] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 25; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 26; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:31, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:31. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:34, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:34 and containing the mutation S176A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:37, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:37 and containing an unprocessed C-terminus.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:40, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:40 and containing the mutation D91N. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:43, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:43 and containing an unprocessed N-terminus. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:46, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:46 and containing an N-terminal Ile deletion. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:49, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:49 and containing the mutation D175N.In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:52, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:52 and containing the mutation S176C. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:55, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:55 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:58, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:58 and containing the mutation H44A.
[0157] In some embodiments, the antibody binding domain of PR3 CAAR comprises a mutant PR3 antibody binding domain containing a mutation at position 4 compared to mature human PR3. In some embodiments, the mutation of the PR3 antibody binding domain is G4P. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO:9 and a spacer having an amino acid sequence as shown in SEQ ID NO:97. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO:9 and a spacer having an amino acid sequence as shown in SEQ ID NO:25. In some embodiments, PR3 CAAR has an amino acid sequence as shown in SEQ ID NO:55.
[0158] In some embodiments, the antibody binding domain of PR3 CAAR comprises a mutant PR3 antibody binding domain containing a mutation at position 44 compared to mature human PR3. In some embodiments, the mutation of the PR3 antibody binding domain is H44A. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 97. In some embodiments, PR3 CAAR comprises an antibody binding domain having an amino acid sequence as shown in SEQ ID NO: 10 and a spacer having an amino acid sequence as shown in SEQ ID NO: 25. In some embodiments, PR3 CAAR has an amino acid sequence as shown in SEQ ID NO: 56.
[0159] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD8a transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 22; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:110, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:110 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:118, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:118 and containing the mutation H44A.
[0160] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD8a transmembrane domain, a 4-1BB costimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 24; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:109, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:109 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:117, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:117 and containing the mutation H44A.
[0161] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), an IgG4 hinge spacer, a CD8a transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 101; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:107, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:107 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:115, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:115 and containing the mutation H44A.
[0162] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), a spacer, a CD8a transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 102; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:108, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:108 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:116, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:116 and containing the mutation H44A.
[0163] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), a spacer, a CD8a transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 100; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:103, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:103 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:111, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:111 and containing the mutation H44A.
[0164] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), a spacer, a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 100; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 26; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, PR3CAAR comprises the amino acid sequence set forth in SEQ ID NO:104, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:104 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:112, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:112 and containing the mutation H44A.
[0165] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), a spacer, a CD8a transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 99; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 98; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:105, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:105 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:113, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:113 and containing the mutation H44A.
[0166] Provided herein are CAARs comprising any PR3 antibody binding domain (such as any described herein), a spacer, a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, the CAAR comprises any PR3 antibody binding domain described herein; a spacer, the spacer being or containing the sequence shown in SEQ ID NO: 99; a transmembrane domain, the transmembrane domain being or containing the sequence shown in SEQ ID NO: 26; and an intracellular signaling domain containing the 4-1BB signaling domain sequence shown in SEQ ID NO: 27 and the CD3 ζ signaling domain sequence shown in SEQ ID NO: 28. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:106, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:106 and containing the mutant G4P. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:114, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:114 and containing the mutation H44A.
[0167] In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:119, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:119 and containing the mutation H44A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:120, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:120 and containing the mutation H44A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:121, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:121 and containing the mutation H44A. In some embodiments of any of the embodiments, the PR3 CAAR comprises the amino acid sequence set forth in SEQ ID NO:122, or an amino acid sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:122 and containing the mutation H44A.
[0168] In some embodiments of any of the provided embodiments, the PR3 CAAR is encoded by a sequence set forth in SEQ ID NOs:59-88 and 144-159, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence set forth in SEQ ID NOs:59-88 and 144-159. In some embodiments of any of the embodiments, PR3CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:59, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:59. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:60, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:60. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:61, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:61.
[0169] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:62, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:62. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:63, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:63. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:64, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:64.
[0170] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:65, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:65. In some embodiments of any of the embodiments, PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:66, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:66. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:67, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:67.
[0171] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:68, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:68. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:69, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:69. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:70, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:70.
[0172] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:71, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:71. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:72, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:72. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:73, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:73.
[0173] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:74, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:74. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:75, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:75. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:76, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:76.
[0174] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:77, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:77. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:78, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:78. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:79, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:79.
[0175] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:80, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:80. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:81, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:81. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:82, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:82.
[0176] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:83, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:83. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:84, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:84. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:85, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:85.
[0177] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:86, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:86. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:87, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:87. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:88, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:88.
[0178] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:144, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:144. In some embodiments of any of the embodiments, PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:145, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:145. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:146, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:146.
[0179] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:147, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:147. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:148, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:148. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:149, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:149.
[0180] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:150, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:150. In some embodiments of any of the embodiments, PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:151, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:151. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:152, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:152.
[0181] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:153, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:153. In some embodiments of any of the embodiments, PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:154, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:154. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:155, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:155.
[0182] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:156, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:156. In some embodiments of any of the embodiments, PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:157, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:157. In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:158, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:158.
[0183] In some embodiments of any of the embodiments, the PR3 CAAR is encoded by the nucleotide sequence set forth in SEQ ID NO:159, or a nucleotide sequence having at least or at least about 85%, at least or at least about 86%, at least or at least about 87%, at least or at least about 88%, at least or at least about 89%, at least or at least about 90%, at least or at least about 91%, at least or at least about 92%, at least or at least about 93%, at least or at least about 94%, at least or at least about 95%, at least or at least about 96%, at least or at least about 97%, at least or at least about 98%, or at least about 99% sequence identity to the nucleotide sequence set forth in SEQ ID NO:159.
[0184] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 29. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 59, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 59. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 59.
[0185] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 30. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 60, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 60. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 60.
[0186] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 31. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 61, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 61. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 61.
[0187] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 32. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 62, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 62 and contains the mutation S176A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 62.
[0188] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 33. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 63, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 63 and contains the mutation S176A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 63.
[0189] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 34. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 64, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 64 and contains the mutation S176A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 64.
[0190] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 35. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 65, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 65 and contains an unprocessed C-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 65.
[0191] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 36. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 66, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 66 and contains an unprocessed C-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 66.
[0192] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 37. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 67, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 67 and contains an unprocessed C-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 67.
[0193] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 38. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 68, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 68 and contains the mutation D91 N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 68.
[0194] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 39. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 69, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 69 and contains the mutation D91 N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 69.
[0195] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 40. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 70, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 70 and contains the mutation D91 N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 70.
[0196] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 41. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 71, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 71 and contains an unprocessed N-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 71.
[0197] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 42. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 72, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 72 and contains an unprocessed N-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 72.
[0198] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 43. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 73, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 73 and contains an unprocessed N-terminus. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 73.
[0199] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 44. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by: SEQ ID NO: 74, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 74 and contains an N-terminal Ile deletion. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 74.
[0200] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 45. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by: SEQ ID NO: 75, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 75 and contains an N-terminal Ile deletion. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 75.
[0201] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 46. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by: SEQ ID NO: 76, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 76 and contains an N-terminal Ile deletion. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 76.
[0202] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 47. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 77, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 77 and contains the mutation D175N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 77.
[0203] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 48. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 78, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 78 and contains the mutation D175N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 78.
[0204] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 49. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 79, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 79 and contains the mutation D175N. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 79.
[0205] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 50. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 80, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 80 and contains the mutation S176C. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 80.
[0206] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 51. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 81, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 81 and contains the mutation S176C. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 81.
[0207] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 52. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 82, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 82 and contains the mutation S176C. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 82.
[0208] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 53. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 83, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 83 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 83.
[0209] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 54. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 84, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 84 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 84.
[0210] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO:55. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:55 and containing a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:55 and containing a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO:55 and containing a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:55 and containing a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 85, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 85 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 85.
[0211] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 56. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 86, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 86 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 86.
[0212] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO:57. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:57 and containing the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:57 and containing the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO:57 and containing the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:57 and containing the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 87, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 87 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 87.
[0213] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 58. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 88, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 88 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 88.
[0214] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 103. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 144, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 144 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 144.
[0215] In some embodiments of any such embodiments, the PR3 CAAR is or comprises the sequence set forth in SEQ ID NO: 104. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 104 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 104 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO: 104 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 104 and comprising a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 145, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 145 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 145.
[0216] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 105. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 146, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 146 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 146.
[0217] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 106. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 147, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 147 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 147.
[0218] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 107. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 148, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 148 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 148.
[0219] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 108. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 149, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 149 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 149.
[0220] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 109. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 150, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 150 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 150.
[0221] In some embodiments of any such embodiments, the PR3 CAAR is or comprises the sequence set forth in SEQ ID NO: 110. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 110 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 110 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO: 110 and comprising a mutant G4P. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 110 and comprising a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 151, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 151 and contains a mutant G4P. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 151.
[0222] In some embodiments of any such embodiments, the PR3 CAAR is or comprises the sequence set forth in SEQ ID NO: 111. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 111 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 111 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO: 111 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 111 and comprising the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 152, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 152 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains an amino acid sequence encoded by SEQ ID NO: 152.
[0223] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 112. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 153, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 153 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 153.
[0224] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 113. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 154, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 154 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 154.
[0225] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 114. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 155, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 155 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 155.
[0226] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 115. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 156, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 156 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 156.
[0227] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 116. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 157, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 157 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 157.
[0228] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 117. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 158, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 158 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 158.
[0229] In some embodiments of any such embodiments, the PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 118. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 159, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 159 and contains the mutation H44A. In some embodiments of any such embodiments, the PR3 CAAR is or contains the amino acid sequence encoded by SEQ ID NO: 159.
[0230] In some embodiments of any such embodiments, the PR3 CAAR is or comprises the sequence set forth in SEQ ID NO: 119. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 119 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 119 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 97% sequence identity to the amino acid sequence set forth in SEQ ID NO: 119 and comprising the mutation H44A. In some embodiments, the PR3 CAAR comprises an amino acid sequence having at least or at least about 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 119 and comprising the mutation H44A.
[0231] In some embodiments of any such embodiments, PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 120. In some embodiments of any such embodiments, PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 121. In some embodiments of any such embodiments, PR3 CAAR is or contains the sequence set forth in SEQ ID NO: 122.
[0232] In some embodiments, provided CAAR-expressing cells exhibit biological activities or functions, including cytotoxic activity, cytokine production, and proliferation capacity.
[0233] In some embodiments, the biological activity or functional activity (such as cytotoxic activity) of the chimeric receptor can be measured using any of a variety of known methods. Activity can be evaluated or determined in vitro or in vivo. In some embodiments, activity can be evaluated after the cell is administered to a subject (e.g., a person). The parameters to be evaluated include the specific binding of engineered or natural T cells or other immune cells to a target binding partner (e.g., PR3-ANCA), which is evaluated, for example, in vivo, for example, by imaging, or in vitro, for example, by ELISA or flow cytometry. In certain embodiments, the ability of engineered cells to destroy target cells can be measured using any suitable method, as described in the examples herein. In some embodiments, the CAAR provided is capable of killing at least 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the cell targets expressing anti-PR3 antibodies. In some embodiments, CAAR is capable of killing at least 65% of the cell targets expressing anti-PR3 antibodies, as evaluated using the assay described in Example 3. Other cytotoxicity assays are known in the art, such as, for example, Kochenderfer et al., J. Immunotherapy, 32 (7): 689-702 (2009) and Herman et al. J. Immunological Methods, 285 (1): 25-40 (2004) described in the cytotoxicity assay. In certain embodiments, the biological activity of the cell can also be measured by measuring the expression and / or secretion of certain cytokines such as interleukin-2 (IL-2), interferon-γ (IFNγ), interleukin-4 (IL-4), TNF-α (TNFα), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), granulocyte-macrophage colony stimulating factor (GM-CSF), CD107a and / or TGF-β (TGFβ). Measurements of cytokines are well known in the art and include, but are not limited to, ELISA, intracellular cytokine staining, flow bead arrays, RT-PCR, ELISPOT, flow cytometry, and bioassays that test the responsiveness (e.g., proliferation) of cells that respond to the relevant cytokines in the presence of a test sample. In some aspects, biological activity is measured by assessing clinical outcomes.
[0234] In some embodiments, the CAARs provided include CAARs that exhibit target-dependent activity or signaling, i.e., signaling activity is measurably absent or at background levels in the absence of a target (e.g., PR3-ANCA). Thus, in some aspects, the CAARs provided do not exhibit tonic signaling or exhibit tonic signaling that is no more than background or tolerable or low levels of tonic signaling. Tonic signaling refers to the presence of CAAR activity (e.g., cytotoxic activity or other functional activity, such as cytokine production) that can occur in the absence of a target (e.g., PR3-ANCA) and is target-independent activity or signaling. In some embodiments, among a plurality of cells expressing a CAAR in a composition, less than or less than about 10%, less than or less than about 9%, less than or less than about 8%, less than or less than about 7%, less than or less than about 5%, less than or less than about 4%, less than or less than about 3%, less than or less than about 2%, or less than or less than about 1% of the cells exhibit tonic signaling and / or antigen-independent activity or signaling. In some embodiments, antigen-independent activity or signaling is represented by off-target killing as described in Example 8.
[0235] In some aspects, reporter cell lines can be used to monitor antigen-independent activity and / or tonic signaling through CAAR-expressing cells. In some embodiments, a T cell line (such as a Jurkat cell line) contains a reporter molecule expressed under the control of an endogenous Nur77 transcriptional regulatory element, such as a fluorescent protein or other detectable molecule (such as a red fluorescent protein). In some embodiments, Nur77 reporter gene expression is cell-intrinsic and depends on signaling through a recombinant reporter, which contains a primary activation signal in a T cell, a signaling domain of a T cell receptor (TCR) component, and / or a signaling domain containing an immunoreceptor tyrosine activation motif (ITAM) (such as a CD3ζ chain). Nur77 expression is generally not affected by other signaling pathways (such as cytokine signaling or toll-like receptor (TLR) signaling), which may act in a non-intrinsic manner to the cell and may not depend on signaling through a recombinant receptor. Therefore, only cells expressing exogenous CAARs containing appropriate signaling regions are able to express Nur77 upon stimulation (e.g., binding of a specific antigen). In some cases, Nur77 expression can also show a dose-dependent response to the amount of stimulus (eg, antigen).
[0236] An exemplary reporter assay for assessing tonic signaling is described in Example 2. In some embodiments, cells transduced with CAAR show antigen-specific activation following exposure to an anti-human PR3 antibody. In some embodiments, the anti-human PR3 antibody is MAB684022. F. Polynucleotides
[0237] Provided are polynucleotides encoding therapeutic proteins containing PR3 antibody binding domains as provided herein. Also provided are polynucleotides encoding CAARs as described herein. Polynucleotides may include those comprising naturally and / or non-naturally occurring nucleotides and bases, for example including those with backbone modifications. The terms "nucleic acid molecule," "nucleic acid," "nucleotide sequence," and "polynucleotide" may be used interchangeably and refer to polymers of nucleotides. Such polymers of nucleotides may contain natural and / or non-natural nucleotides and include, but are not limited to, DNA, RNA, and PNA. "Nucleic acid sequence" refers to a linear sequence of nucleotides that constitute a nucleic acid molecule or polynucleotide.
[0238] Provided are polynucleotides containing nucleic acids encoding any PR3 antibody binding domain constructs described herein. Also provided are polynucleotides containing nucleic acids encoding any PR3 CAAR described herein. In some embodiments, PR3 CAAR contains multiple domains, and all CAARs are encoded in more than one polynucleotide (e.g., two or more polynucleotides). In some embodiments, the polynucleotide is contained in a vector.
[0239] In some cases, the polynucleotide encoding PR3 CAAR contains a signal sequence encoding a signal peptide, which in some cases is encoded upstream of the nucleic acid sequence encoding PR3 CAAR or joined at the 5' end of the nucleic acid sequence encoding the antigen binding domain. In some cases, the polynucleotide containing the nucleic acid sequence encoding PR3 CAAR contains a signal sequence encoding a signal peptide. In some aspects, the signal sequence can encode a signal peptide derived from a natural polypeptide. In other aspects, the signal sequence can encode a heterologous or non-natural signal peptide. In some aspects, non-limiting exemplary signal peptides include the signal peptide of the CD33 signal peptide shown in SEQ ID NO:21. In some aspects, non-limiting exemplary signal peptides include the signal peptide of the PR3 signal peptide shown in SEQ ID NO:123. In some cases, the polynucleotide encoding PR3 CAAR may contain a nucleic acid sequence encoding another molecule (such as a replacement marker or other marker), or may contain another component, such as a promoter, a regulatory element and / or a polycistronic element. In some embodiments, the nucleic acid sequence encoding PR3 CAAR can be operably connected to any other component.
[0240] In some embodiments, the polynucleotide contains a nucleic acid sequence encoding any of the PR3 CAARs described in Section IF. In some embodiments, the nucleic acid sequence includes any of the nucleic acid sequences described in Section IF.
[0241] In some embodiments, a polynucleotide containing a nucleic acid sequence encoding a PR3 antibody binding domain construct or a PR3CAAR containing a PR3 antibody binding domain construct is provided. In some embodiments of any embodiment, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain construct, the nucleic acid comprising a sequence as shown in any one of SEQ ID NOs: 11-20, or a nucleic acid sequence having at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 11-20.
[0242] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence shown in SEQ ID NO:11, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:11. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence shown in SEQ ID NO:12, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:12. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO:13, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:13. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence set forth in SEQ ID NO:14, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:14. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence set forth in SEQ ID NO:15, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:15.
[0243] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO:16, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:16. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence set forth in SEQ ID NO:17, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:17. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO:18, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:18. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain, the nucleic acid comprising the sequence set forth in SEQ ID NO:19, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:19. In some embodiments, the polynucleotide contains a nucleic acid encoding a PR3 antibody binding domain comprising the sequence set forth in SEQ ID NO:20, or a nucleic acid sequence that is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:20.
[0244] Also provided are polynucleotides optimized for codon usage and / or elimination of splice sites (such as hidden splice sites).In some embodiments, polynucleotides are modified to optimize codon usage.In some embodiments, polynucleotides are codon optimized for expression in human cells (such as human T cells such as primary human T cells).In some embodiments, polynucleotides (such as those encoding any PR3 constructs or PR3 CAARs provided herein) are modified or have been modified to reduce heterogeneity or contain one or more nucleic acid sequences observed herein (such as by optimization methods) to cause polypeptides (such as CAARs) to be improved compared to those containing different reference sequences or those that are not optimized.In some embodiments, polynucleotides are optimized by splice site elimination.Such features include RNA heterogeneity (such as RNA heterogeneity caused by the presence of one or more splice sites (such as one or more hidden splice sites)) and / or the expression and / or surface expression of the improvement of the protein encoded, such as the expression level, uniformity or consistency of the increase in the cell or different therapeutic cell compositions engineered to express the polypeptide. In some embodiments, the polynucleotides may be codon optimized for expression in human cells.
[0245] Generally, the genomic nucleic acid sequence in mammalian cells undergoes co-transcriptional processing or is processed immediately after transcription, wherein the nascent precursor messenger RNA (pre-mRNA) transcribed from the genomic deoxyribonucleic acid (DNA) sequence is edited in some cases by means of splicing to remove introns, and then the exons in the eukaryotic cell are connected. The consensus sequence of the splice site is known, and in some aspects, the specific nucleotide information defining the splice site may be complex, and may not be easy to see based on the available methods. Concealed splice sites are splice sites that are unpredictable and variably activated based on standard consensus sequences. Therefore, the variable splicing of pre-mRNA at concealed splice sites leads to the heterogeneity of the mRNA product transcribed after expression in eukaryotic cells.
[0246] The polynucleotides produced for expressing transgenes are usually constructed from nucleic acid sequences that do not contain introns, such as complementary DNA (cDNA) or portions thereof. Therefore, it is expected that splicing of such sequences does not occur. However, the presence of hidden splicing sites within the cDNA sequence may lead to unexpected or undesirable splicing reactions and heterogeneity in the transcribed mRNA. This heterogeneity leads to the translation of unexpected protein products, such as truncated protein products with variable amino acid sequences that exhibit modified expression and / or activity.
[0247] In some embodiments, elimination of splice sites (e.g., cryptic splice sites) can improve or optimize expression of transgenic products (e.g., polypeptides translated from transgenics, such as PR3 CAAR polypeptides). Splicing at cryptic splice sites of an encoded transgenic (e.g., an encoded PR3 CAAR molecule) can result in reduced protein expression (e.g., expression on the cell surface) and / or reduced function (e.g., reduced intracellular signaling). In some embodiments, the polynucleotides encoding the PR3 CAAR protein have been optimized to reduce or eliminate cryptic splice sites. In some embodiments, the polynucleotides encoding the PR3 CAAR protein have been optimized for codon expression, and / or one or more sequences are present therein (e.g., sequences identified by methods or observations herein regarding splice sites), and / or an identified splice site (e.g., any identified splice site herein) is not present therein.
[0248] RNA heterogeneity can be determined by any of a variety of methods provided herein or described or known. In some embodiments, RNA heterogeneity of transcribed nucleic acids is determined by amplifying transcribed nucleic acids, such as by reverse transcriptase polymerase chain reaction (RT-PCR), followed by detecting one or more differences in one or more amplified products, such as size differences. In some embodiments, RNA heterogeneity is determined based on the number of amplified products of different sizes or the ratio of amplified products of various sizes. In some embodiments, RNA (such as total RNA or cytoplasmic polyadenylated RNA) is harvested from cells expressing the transgenic to be optimized, and amplified by reverse transcriptase polymerase chain reaction (RT-PCR) using primers specific to the 5' untranslated region (5'UTR) and primers specific to the 3' untranslated region (3'UTR) or primers specific to sequences within the transgenic, the 5' untranslated region corresponding to a portion of a promoter sequence in an expression vector in some cases, and the 3' untranslated region is located downstream of the expressed transgenic in the transcribed RNA sequence. In a specific embodiment, the transgene is amplified using at least one primer complementary to a sequence in the 5' untranslated region (UTR) and at least one primer complementary to a sequence in the 3' untranslated region (UTR). RNA (such as messenger RNA) can be parsed and analyzed for heterogeneity by several methods. Non-limiting exemplary methods include agarose gel electrophoresis, chip-based capillary electrophoresis, analytical centrifugation, field flow fractionation, and chromatography (such as size exclusion chromatography or liquid chromatography).
[0249] In some embodiments, the polynucleotides provided encoding the PR3 CAARs provided herein or the PR3 constructs provided herein comprise modifications to remove one or more splice donor and / or acceptor sites that may contribute to splicing events and / or reduced expression and / or increased RNA heterogeneity. In some embodiments, the polynucleotides provided are modified in one or more polynucleotides in the spacer region to eliminate or reduce splicing events.
[0250] Exemplary PR3 CAARs and polynucleotides containing nucleic acid sequences encoding all or a portion, fragment or domain of any exemplary CAAR described herein are provided. Polynucleotides encoding PR3 CAARs are also provided herein. In some embodiments, CAARs can be encoded by more than one different polynucleotide (e.g., two or more polynucleotides). In some embodiments of any such embodiments, two or more polynucleotides can each contain nucleic acids encoding a portion, fragment or domain of CAAR. In some cases, the polynucleotides also include a CD33 signal sequence or a PR3 signal sequence. The polynucleotide sequences of exemplary PR3 CAARs are shown in SEQ ID NOs: 59-88 and 144-159 encoding the amino acid sequences shown in SEQ ID NOs: 29-58 and 103-118.
[0251] In some embodiments of any of the embodiments, the polynucleotide contains a sequence as set forth in SEQ ID NOs:59-88 and 144-159, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence as set forth in SEQ ID NOs:59-88 and 144-159. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 59, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 59. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 59. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:60, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:60. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:60. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:61, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:61. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:61.
[0252] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:68, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:68. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:68. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 69, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 69. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 69. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:70, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:70. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO:70.
[0253] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 83, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 83. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 83. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 84, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 84. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 84. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 85, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 85. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 85.
[0254] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 86, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 86. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 86. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 87, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 87. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 87. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 88, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 88. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 88.
[0255] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 144, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 144. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 144. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 145, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 145. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 145. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 146, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 146. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 146.
[0256] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 147, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 147. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 147. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 148, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 148. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 148. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 149, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 149. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 149.
[0257] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 150, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 150. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 150. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 151, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 151. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 151. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 152, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 152. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 152.
[0258] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 153, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 153. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 153. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 154, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 154. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 154. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 155, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 155. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 155.
[0259] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 156, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 156. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 156. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 157, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 157. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 157. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 158, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 158. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 158.
[0260] In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 159, or a sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 159. In some embodiments of any of the embodiments, the polynucleotide comprises the sequence set forth in SEQ ID NO: 159.
[0261] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence shown in SEQ ID NOs:29-58 or 103-122, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence shown in SEQ ID NOs:29-58 or 103-122. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 29, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 29. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 29. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 30, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 30. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 30. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 31, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 31. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 31.
[0262] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 38, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 38. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 38. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 39, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 39. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 39. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO:40, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:40. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO:40.
[0263] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 53, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 53. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 53. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 54, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 54. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 54. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 55, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 55. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 55.
[0264] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 56, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 56. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 56. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 57, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 57. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 57. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 58, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 58. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 58.
[0265] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 103, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 103. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 103. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 104, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 104. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 104. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 105, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 105. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 105. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 106, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 106. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 106.
[0266] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 107, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 107. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 107. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 108, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 108. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 108. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 109, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 109. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 109. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 110, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 110. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 110.
[0267] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 111, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 111. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 111. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 112, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 112. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 112. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 113, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 113. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 113. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 114, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 114. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 114.
[0268] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 115, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 115. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 115. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 116, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 116. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 116. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 117, or a sequence encoding a polypeptide sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 117. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 117. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 118, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 118. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 118.
[0269] In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 119, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 119. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 119. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 120, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 120. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 120. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 121, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 121. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 121. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 122, or a sequence encoding a polypeptide sequence that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 122. In some embodiments of any of the embodiments, the polynucleotide contains a nucleic acid encoding the sequence set forth in SEQ ID NO: 122. II. Engineered Cells
[0270] Also provided are cells, such as engineered cells containing CAAR, such as CAAR containing an extracellular domain comprising a PR3 antibody binding domain construct as described herein. Also provided are populations of such cells, compositions containing such cells and / or enriched in such cells, such as cells expressing PR3CAAR constituting at least 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or higher percentages of total cells or cells of a certain type (such as T cells or CD8+ or CD4+ cells) in the composition. Compositions include pharmaceutical compositions and formulations for administration (such as for adoptive cell therapy). Also provided are methods of treating cells and compositions for administration to subjects (e.g., patients).
[0271] Genetically engineered cells expressing PR3 CAAR are also provided. The cell is typically a eukaryotic cell, such as a mammalian cell, and is typically a human cell. In some embodiments, the cell is derived from blood, bone marrow, lymph or lymphoid organs, and is a cell of the immune system, such as a cell of innate or adaptive immunity, such as bone marrow or lymphocytes, including lymphocytes, typically T cells and / or NK cells. Other exemplary cells include stem cells, such as pluripotent stem cells and multipotent stem cells, including induced pluripotent stem cells (iPSC). The cell is typically a primary cell, such as those directly isolated from a subject and / or isolated and frozen from a subject.
[0272] In certain embodiments, the cell expressing PR3 CAAR is an induced pluripotent stem cell (iPSC). In some embodiments, the cell is an iPSC-derived cell that has been differentiated from an iPSC.
[0273] In some embodiments, iPSC is differentiated into T cells or NK cells. In some embodiments, the method for differentiating iPSC into T cells or NK cells is described in, for example, disclosed PCT application numbers WO 2022120334, WO 2022216514, and WO2022216624. In certain embodiments, iPSC can be differentiated by any method known in the art. Exemplary methods are described in US 8846395, US 8945922, US 8318491, WO 2010 / 099539, WO 2012 / 109208, WO 2017 / 070333, WO 2017 / 179720, WO 2016 / 010148, WO 2018 / 048828, and WO 2019 / 157597, each of which is incorporated herein by reference in its entirety. In some embodiments, the differentiated T cells are γ-δ T cells. In some embodiments, the differentiated T cells are α-β T cells. The differentiation protocol can use feeder cells or can be feeder-free. As used herein, "feeder cells" or "feeders" are terms describing a type of cell that is co-cultured with a second type of cell to provide an environment in which the second type of cell can grow, expand or differentiate, because the feeder cells provide stimulation, growth factors, and nutrients for supporting the second cell type.
[0274] In some embodiments, the iPSC-derived cells are NK cells produced by a method of differentiating iPSC cells into NK cells by subjecting the cells to a differentiation protocol that includes adding recombinant human IL-12p70 for the final 24 hours of culture.
[0275] In some embodiments, iPSC is modified by genome engineering. The use of iPSC enables cell engineering to produce a controlled cell bank of modified cells, which can be expanded and differentiated into desired immune effector cells, thereby providing a large amount of homogeneous allogeneic therapeutic products. In some embodiments, genome engineering includes targeted editing, which may include but is not limited to deletion, insertion or insertion / deletion by any other functional changes of CRISPR, ZFN, TALEN, homing nuclease, homologous recombination or these methods. In some embodiments, genome engineering includes one or more exogenous polynucleotides integrated at one or more loci on the chromosome of iPSC. In some embodiments, iPSC or cells differentiated therefrom are engineered with genome modifications that enhance the therapeutic properties of derived cells. In some embodiments, the resulting differentiated cells derived from engineered iPSC contain modifications that reduce cellular immunity to use cells as allogeneic cell products. Exemplary genomic modifications are described, for example, in published PCT application numbers WO2022120334, WO 2022216514, and WO 2022216624.
[0276] In some embodiments, iPSC or iPSC-derived cells (e.g., T cells or NK cells) are modified by editing one or more genes (e.g., knocking out) or inserting one or more exogenous genes (e.g., knocking in) that reduce cellular immunity. In some embodiments, cells are modified by deleting one or more target genes or inserting one or more exogenous genes to reduce cellular immunity or regulate its activity.
[0277] In some embodiments, the cells are allogeneic cells.In some embodiments, the cells are engineered to be immunoreduced.
[0278] In some embodiments, the cells are autologous cells.
[0279] In some embodiments, the cell is a T cell. In some embodiments, the cell includes one or more subsets of T cells or other cell types, such as the entire T cell population, CD4 + Cells, CD8 + Cells and subpopulations thereof, such as those defined by function, activation state, maturity, differentiation potential, expansion, recirculation, localization and / or persistence capacity, antigen specificity, antigen receptor type, presence in a specific organ or compartment, marker or cytokine secretion characteristics, and / or degree of differentiation. In some embodiments, provided herein are T cells comprising a provided CAAR. In some embodiments, the T cells are CD4+ T cells. In some embodiments, the T cells are CD8+ T cells.
[0280] Regarding the subject to be treated, the cell can be allogeneic and / or autologous. The method includes a ready-made method. In some aspects, as for the prior art, the cell is pluripotent and / or multipotent, such as stem cells, such as induced pluripotent stem cells (iPSC). In some embodiments, the method includes separating cells from the subject, preparing, processing, culturing and / or engineering them, as described herein, and reintroducing them into the same patient before or after cryopreservation.
[0281] T cells and / or CD4 + and / or CD8 + T cell subtypes and subsets include naive T (T N ) cells, effector T cells (T EFF ), memory T cells and their subtypes (such as stem cell memory T (T SCM ), central memory T(T CM ), effect memory T(T EM ) or terminally differentiated effector memory T cells), tumor infiltrating lymphocytes (TIL), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosa-associated constant T (MAIT) cells, naturally occurring and adaptive regulatory T (Treg) cells, helper T cells (such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper T cells), α / β T cells and δ / γ T cells.
[0282] In some embodiments, the cell is a natural killer (NK) cell. In some embodiments, the cell is a monocyte or a granulocyte, such as a bone marrow cell, a macrophage, a neutrophil, a dendritic cell, a mast cell, an eosinophil, and / or a basophil.
[0283] Also provided herein is a cell population, wherein the cells of the population include the CAAR provided. In some embodiments, the cell population is a cell from the peripheral blood of a subject, such as a cell from a subject to be treated (e.g., by autologous adoptive cell therapy). In some embodiments, a cell population is obtained by apheresis. In some embodiments, a cell population is obtained by leukocyte apheresis. In some embodiments, the cell population is a peripheral blood mononuclear cell (PBMC). In some embodiments, in the cells in the population, greater than or greater than about 30%, greater than or greater than about 40%, greater than or greater than about 50%, greater than or greater than about 60%, greater than or greater than about 70% or more of the cell is a T cell.
[0284] Also provided herein is a T cell group, wherein the T cell of the group comprises the CAAR provided. In some embodiments, the T cell group is enriched in a biological sample (e.g., blood, leukocyte apheresis or apheresis sample) selected from a subject. In some embodiments, the T cell group is rich in CD3+ cells. In some embodiments, the T cell group contains greater than or greater than about 75% CD3+ T cells, such as greater than or greater than about 80% CD3+ T cells, greater than or greater than about 85% CD3+ T cells, greater than or greater than about 90% CD3+ T cells or greater than or greater than about 95% CD3+ T cells. In some embodiments, the T cell group contains greater than or greater than about 95% CD3+ T cells. In some embodiments, the T cell group contains CD4+ and CD8+ T cells. In some embodiments, CD4+ and CD8+ T cells are present in a ratio of about 1:3 to 3:1, such as 1:2 to 2:1, such as or about 1:1. In some embodiments, the T cell population contains greater than or greater than about 75% CD4+ and CD8+ T cells, such as greater than or greater than about 80% CD4+ and CD8+ T cells, greater than or greater than about 85% CD4+ and CD8+ T cells, greater than or greater than about 90% CD4+ and CD8+ T cells, or greater than or greater than about 95% CD4+ and CD8+ T cells. In some embodiments, the T cell population contains greater than or greater than about 95% CD4+ and CD8+ T cells.
[0285] In some embodiments, at least 25% of the cells in the population express CAAR. In some embodiments, at least or about 30%, at least or about 40%, at least or about 50%, at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, or at least or about 90% or more of the cells in the population express CAAR. In some embodiments, expression refers to positive surface expression of CAAR on the surface of a cell, e.g., as determined by flow cytometry.
[0286] In some embodiments, the cell includes one or more polynucleotides introduced via genetic engineering, and the recombinant or genetically engineered product of such polynucleotides is expressed thereby. In some embodiments, the polynucleotide is heterologous, i.e., not usually present in the cell or in a sample obtained from the cell, such as a polynucleotide obtained from another organism or cell, for example, the polynucleotide is not usually found in the engineered cell and / or the organism from which the cell is derived. In some embodiments, the polynucleotide is not a naturally occurring polynucleotide such as a polynucleotide not found in nature, including nucleic acids comprising chimeric combinations of polynucleotides encoding various domains from a variety of different cell types. In some embodiments, the cell (e.g., engineered cell) comprises a vector as described herein (e.g., a viral vector, an expression vector, etc.), such as a vector comprising a nucleic acid encoding a PR3 CAAR as described herein. A. Vectors and Methods for Genetic Engineering
[0287] Also provided are methods, nucleic acids, compositions and kits for expressing PR3 CAAR and for producing genetically engineered cells expressing the CAAR. In some embodiments, one or more CAAR genes can be engineered into a cell or cells. Genetic engineering generally involves introducing nucleic acids encoding recombinant or engineered components into cells, such as by retroviral transduction, transfection or transformation.
[0288] Nucleic acid can include those comprising natural and / or non-naturally occurring nucleotides and bases, for example including those with backbone modifications. The terms "nucleic acid molecule", "nucleic acid" and "polynucleotide" can be used interchangeably, and refer to polymers of nucleotides. Such polymers of nucleotides can contain natural and / or non-natural nucleotides, and include but are not limited to DNA, RNA and PNA. "Nucleic acid sequence" refers to the linear sequence of nucleotides constituting nucleic acid molecules or polynucleotides. In some aspects, the nucleic acid sequence encoding at least a portion of the antibody or its antigen-binding fragment (such as scFv), conjugate, receptor (e.g., CAAR) provided herein can be optimized (e.g., codon optimized) for expression in human cells and / or optimized to reduce or eliminate hidden splice sites.
[0289] In some embodiments, the polynucleotide further comprises one or more additional sequences, such as sequences encoding one or more additional molecules (such as markers), or promoters, regulatory elements and / or polycistronic elements. In some embodiments, the polynucleotides provided include any polynucleotides described herein.
[0290] Also provided are vectors containing nucleic acids (e.g., polynucleotides) and engineered cells containing the vectors, such as engineered immune cells expressing PR3 CAAR. Also provided are methods for engineering cells such as immune cells to express PR3 CAAR. The nucleic acids may encode an amino acid sequence comprising: a wild-type PR3 antibody binding domain or a mutant PR3 antibody binding domain as an extracellular antigen binding domain; a transmembrane domain and an intracellular domain (e.g., CD3ζ and a costimulatory signaling domain).
[0291] In other embodiments, one or more vectors (e.g., expression vectors) comprising such polynucleotides are provided. In other embodiments, host cells comprising such polynucleotides are provided. In one such embodiment, ...
Claims
1. A chimeric autoantibody receptor (CAAR), comprising: (a) an extracellular proteinase 3 (PR3) antibody binding domain, wherein the PR3 antibody binding domain is a mutant PR3 protein having reduced enzymatic activity compared to a wild-type PR3 protein having a sequence as shown in SEQ ID NO: 1; (b) a transmembrane region; and (c) Intracellular signal transduction region.
2. The CAAR of claim 1, further comprising a spacer between the extracellular PR3 antibody binding domain and the transmembrane domain.
3. The CAAR of claim 1 or 2, wherein the mutant PR3 protein comprises an amino acid substitution at a position selected from the group consisting of G4, H44, D91, D175, and S176 numbered with reference to the positions in SEQ ID NO:
1.
4. The CAAR of claim 3, wherein the amino acid substitution is selected from the group consisting of G4P, H44A, D91N, D175N, S176A, and S176C.
5. The CAAR of claim 3, wherein the amino acid substitution is a conservative substitution selected from the group consisting of G4P, H44A, D91N, D175N, S176A, and S176C.
6. The CAAR of claim 1 or 2, wherein the mutant PR3 protein comprises an amino acid substitution in or near the catalytic triad, wherein the amino acid substitution is in an active site residue selected from the group consisting of: H44, D91, and S176 as numbered with reference to SEQ ID NO:
1.
7. The CAAR of claim 6, wherein the amino acid substitution is selected from the group consisting of H44A, D91N, S176A, and S176C.
8. The CAAR of any one of claims 1-7, wherein the mutant PR3 protein comprises an amino acid substitution at position H44 with reference to the position numbering in SEQ ID NO:
1.
9. The CAAR of claim 1 or 2, wherein the mutant PR3 protein comprises an amino acid substitution at a position that interferes with the formation of a substrate binding pocket.
10. The CAAR of any one of claims 1-3 and 9, wherein the mutant PR3 protein comprises an amino acid substitution at position G4 with reference to the position numbering in SEQ ID NO:
1.
11. The CAAR according to any one of claims 3 to 10, wherein the mutant PR3 protein comprises 1, 2, 3, 4 or 5 amino acid substitutions compared to the wild-type PR3 shown in SEQ ID NO:
1.
12. The CAAR of any one of claims 3-11, wherein the mutant PR3 protein comprises a single amino acid substitution compared to SEQ ID NO:
1.
13. The CAAR of any one of claims 3-12, wherein the mutant PR3 protein comprises the amino acid substitution G4P.
14. A CAAR, comprising: (a) PR3 antibody binding domain; (b) a transmembrane region; and (c) Intracellular signal transduction region, The PR3 antibody binding domain is a mutant PR3 protein comprising the amino acid substitution G4P.
15. The CAAR of any one of claims 1-5 and 7-14, wherein the PR3 antibody binding domain comprises an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:
9.
16. The CAAR of any one of claims 1-5 and 7-15, wherein the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO:
9.
17. The CAAR according to any one of claims 1-5 and 7-16, wherein the amino acid sequence of the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO:
9.
18. The CAAR of any one of claims 3-7, wherein the mutant PR3 protein comprises the amino acid substitution H44A.
19. A CAAR, comprising: (a) PR3 antibody binding domain; (b) a transmembrane region; and (c) Intracellular signal transduction region, The PR3 antibody binding domain is a mutant PR3 protein comprising the amino acid substitution H44A.
20. The CAAR of any one of claims 1-6, 11 and 19, wherein the PR3 antibody binding domain comprises an amino acid sequence that exhibits at least 90% sequence identity to SEQ ID NO:
10.
21. The CAAR of any one of claims 1-6, 11, 19 and 20, wherein the PR3 antibody binding domain comprises the amino acid sequence shown in SEQ ID NO:
10.
22. The CAAR according to any one of claims 1-6, 11 or 19-21, wherein the amino acid sequence of the PR3 antibody binding domain consists of the sequence shown in SEQ ID NO:
10.
23. The CAAR of any one of claims 1-22, wherein the transmembrane region is or comprises a transmembrane domain from CD4, CD28 or CD8.
24. The CAAR according to any one of claims 1-23, wherein the transmembrane region is or comprises a transmembrane domain from CD28, optionally human CD28.
25. The CAAR of any one of claims 1-24, wherein the transmembrane region is or comprises SEQ ID NO:26 or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:
26.
26. The CAAR of any one of claims 1-25, wherein the transmembrane region is shown in SEQ ID NO:
26.
27. The CAAR of any one of claims 1-22, wherein the transmembrane region is or comprises a transmembrane domain from CD8a, optionally human CD8a.
28. The CAAR of any one of claims 1-22 and 27, wherein the transmembrane region is or comprises SEQ ID NO: 98 or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:
98.
29. The CAAR of any one of claims 1-22, 27, and 28, wherein the transmembrane region is shown in SEQ ID NO:
98.
30. The CAAR of any one of claims 1-29, wherein the intracellular signaling region comprises an intracellular signaling domain capable of inducing a primary activation signal in a T cell.
31. The CAAR of claim 30, wherein the intracellular signaling domain is a domain from a T cell receptor (TCR) component and / or comprises an immunoreceptor tyrosine-based activation motif (ITAM).
32. The CAAR of claim 30 or claim 31, wherein the intracellular signaling domain is the cytoplasmic signaling domain of the CD3-zeta (CD3ζ) chain, optionally the human CD3ζ chain.
33. The CAAR of any one of claims 30-32, wherein the intracellular signaling domain comprises the sequence shown in SEQ ID NO:28, or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:
28.
34. The CAAR of any one of claims 30-33, wherein the intracellular signaling domain consists of the sequence shown in SEQ ID NO:
28.
35. The CAAR of any one of claims 30-34, wherein the intracellular signaling region further comprises a co-stimulatory signaling region.
36. The CAAR of claim 35, wherein the co-stimulatory signaling region is between the transmembrane region and the intracellular signaling domain.
37. The CAAR of claim 35 or claim 36, wherein the co-stimulatory signaling region comprises an intracellular signaling domain of a T cell co-stimulatory molecule or a signaling portion thereof.
38. The CAAR of any one of claims 35-37, wherein the co-stimulatory signaling region comprises an intracellular signaling domain of CD28, 4-1BB, or ICOS.
39. The CAAR of any one of claims 35-38, wherein the co-stimulatory signaling region comprises the intracellular signaling domain of 4-1BB, optionally human 4-1BB.
40. The CAAR of any one of claims 35-39, wherein the co-stimulatory signaling region comprises the sequence shown in SEQ ID NO:27 or an amino acid sequence having at least or at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:
27.
41. The CAAR of any one of claims 35-40, wherein the co-stimulatory signaling region is shown in SEQ ID NO:
27.
42. The CAAR of any one of claims 2-41, wherein the spacer comprises at least a portion of an immunoglobulin or a variant thereof.
43. The CAAR of any one of claims 2-42, wherein the spacer comprises a hinge region of an immunoglobulin or a variant thereof.
44. The CAAR of claim 43, wherein the hinge region of an immunoglobulin is an IgG4 hinge region, optionally a human IgG4 hinge region or a variant thereof.
45. The CAAR of any one of claims 42-44, wherein the spacer comprises a variant IgG4 hinge region comprising a substitution of amino acids CPSC to CPPC compared to a wild-type IgG4 hinge region.
46. The CAAR of any one of claims 2-45, wherein the spacer is less than 15 amino acids in length.
47. The CAAR of any one of claims 2-45, wherein the spacer is between 12 and 15 amino acids in length.
48. The CAAR of any one of claims 2-47, wherein the spacer comprises the sequence shown in SEQ ID NO:22 or SEQ ID NO:
23.
49. The CAAR of any one of claims 2-48, wherein the spacer is shown in SEQ ID NO:
22.
50. The CAAR of any one of claims 2-45 and 48, wherein the spacer is between 100 and 150 amino acids in length, optionally between 110 and 130 amino acids in length.
51. The CAAR of any one of claims 2-45, 48, and 50, wherein the spacer comprises a hinge region of an immunoglobulin and a CH3 region of an immunoglobulin.
52. The CAAR of claim 51, wherein the spacer comprises an IgG4 hinge region or a variant thereof and an IgG4 CH3 region.
53. The CAAR of any one of claims 2-45, 48, and 50-52, wherein the spacer comprises the sequence shown in SEQ ID NO:24 or SEQ ID NO:
96.
54. The CAAR of any one of claims 2-45, 48, and 50-53, wherein the spacer is shown in SEQ ID NO:
24.
55. The CAAR of any one of claims 2-45 and 48, wherein the spacer is between 200 and 250 amino acids in length, optionally between 220 and 240 amino acids in length.
56. The CAAR of any one of claims 2-45, 48, and 55, wherein the spacer comprises a hinge region of an immunoglobulin, a CH2 region of an immunoglobulin, or a chimeric CH2 region of two different immunoglobulins and a CH3 region of an immunoglobulin.
57. The CAAR of claim 56, wherein the spacer comprises an IgG4 hinge region or a variant thereof, a chimeric CH2 region comprising a portion of IgG4 CH2 and a portion of IgG2 CH2 (IgG2 / 4 CH2 region), and an IgG4 CH3 region.
58. The CAAR of any one of claims 2-45, 48, and 55-57, wherein the spacer comprises the sequence shown in SEQ ID NO: 25 or SEQ ID NO:
97.
59. The CAAR of any one of claims 2-45, 48, and 55-58, wherein the spacer is shown in SEQ ID NO:
25.
60. The CAAR of any one of claims 2-41, 46, and 47, wherein the spacer comprises amino acids GGGGS (SEQ ID NO: 99).
61. The CAAR of any one of claims 2-41, 46, 47, and 60, wherein the spacer is shown in SEQ ID NO:
99.
62. The CAAR of any one of claims 2-41, 46, 47, and 60, wherein the spacer is shown in SEQ ID NO:
100.
63. The CAAR of any one of claims 1-58, wherein the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to a sequence as shown in any one of SEQ ID NOs:29, 30, 31, 38, 39, 40, 53, 54, 55, 56, 57, 58, 104, 110, or 111, optionally wherein the CAAR comprises a sequence as shown in any one of SEQ ID NOs:29, 30, 31, 38, 39, 40, 54, 55, 56, 57, 58, 59, 104, 110, or 111.
64. A CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO: 9; (b) a spacer comprising the sequence shown in SEQ ID NO: 25; (c) a transmembrane region comprising the sequence shown in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence shown in SEQ ID NO: 27; and (e) An intracellular signaling region comprising the sequence shown in SEQ ID NO:
28.
65. A CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO:55, wherein the amino acid sequence comprises a G4P mutation numbered with reference to positions in SEQ ID NO:
1.
66. The CAAR of claim 65, wherein the CAAR comprises the amino acid sequence shown in SEQ ID NO:
55.
67. A CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO: 10; (b) a spacer comprising the sequence shown in SEQ ID NO: 24; (c) a transmembrane region comprising the sequence shown in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence shown in SEQ ID NO: 27; and (e) An intracellular signaling region comprising the sequence shown in SEQ ID NO:
28.
68. A CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO:57, wherein the amino acid sequence comprises an H44A mutation numbered with reference to positions in SEQ ID NO:
1.
69. The CAAR of claim 68, wherein the CAAR comprises the amino acid sequence shown in SEQ ID NO:
57.
70. A CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO: 9; (b) a spacer comprising the sequence shown in SEQ ID NO: 100; (c) a transmembrane region comprising the sequence shown in SEQ ID NO: 26; (d) a co-stimulatory signaling region comprising the sequence shown in SEQ ID NO: 27; and (e) An intracellular signaling region comprising the sequence shown in SEQ ID NO:
28.
71. A CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 104, wherein the amino acid sequence comprises a G4P mutation numbered with reference to positions in SEQ ID NO:
1.
72. The CAAR of claim 71, wherein the CAAR comprises the amino acid sequence shown in SEQ ID NO:
104.
73. A CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO: 9; (b) a spacer comprising the sequence shown in SEQ ID NO: 22; (c) a transmembrane region comprising the sequence shown in SEQ ID NO:98; (d) a co-stimulatory signaling region comprising the sequence shown in SEQ ID NO: 27; and (e) An intracellular signaling region comprising the sequence shown in SEQ ID NO:
28.
74. A CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 110, wherein the amino acid sequence comprises a G4P mutation numbered with reference to positions in SEQ ID NO:
1.
75. The CAAR of claim 74, wherein the CAAR comprises the amino acid sequence shown in SEQ ID NO:
110.
76. A CAAR comprising: (a) a PR3 antibody binding domain comprising the sequence shown in SEQ ID NO: 10; (b) a spacer comprising the sequence shown in SEQ ID NO: 100; (c) a transmembrane region comprising the sequence shown in SEQ ID NO:98; (d) a co-stimulatory signaling region comprising the sequence shown in SEQ ID NO: 27; and (e) An intracellular signaling region comprising the sequence shown in SEQ ID NO:
28.
77. A CAAR comprising an amino acid sequence exhibiting at least 90% sequence identity to SEQ ID NO: 111 or 119, wherein the amino acid sequence comprises an H44A mutation numbered with reference to positions in SEQ ID NO:
1.
78. The CAAR of claim 77, wherein the CAAR comprises the amino acid sequence shown in SEQ ID NO: 111 or 119.
79. The CAAR of any one of claims 1-78, wherein the CAAR is capable of being specifically bound by an anti-PR3 anti-neutrophil cytoplasmic antibody (PR3-ANCA).
80. The CAAR of any one of claims 1-79, wherein the PR3 antibody binding domain comprises at least 2, 3, 4, 5, 6, or 7 epitopes recognized by anti-PR3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA).
81. The CAAR of claim 80, wherein the epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO:90), ANCA3 (PGSHFCGG, SEQ ID NO:91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO:92), ANCA5 (FLNNYDAE, SEQ ID NO:93), ANCA6 (PVPHGTQC, SEQ ID NO:94) and ANCA7 (CFGDSGGP, SEQ ID NO:95).
82. The CAAR of any one of claims 1-81, wherein the CAAR is specific for PR3-reactive B cells.
83. The CAAR of any one of claims 1-82, wherein Td-tomato is knocked in at the endogenous Nur77 locus and Jurkat reporter cells transduced with the CAAR exhibit less than or less than about 25%, less than or less than about 20%, less than or less than about 15%, less than or less than about 10%, less than or less than about 9%, less than or less than about 8%, less than or less than about 7%, less than or less than about 5%, less than or less than about 4%, less than or less than about 3%, less than or less than about 2%, or less than or less than about 1% tonic signaling as measured by fluorescence of Td-Tomato by flow cytometry and determined as the total percentage of cells expressing Td-Tomato in the transduced Jurkat reporter cells.
84. The CAAR of any one of claims 1-83, wherein cells transduced with the CAAR show antigen-specific activation after exposure to an anti-human PR3 antibody.
85. The CAAR of claim 83 or 84, wherein the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to the sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110 and 111.
86. The CAAR of claim 85, wherein the CAAR comprises a sequence as set forth in any one of SEQ ID NOs: 55, 57, 104, 110, and 111.
87. The CAAR of any one of claims 1-86, wherein the CAAR is capable of killing at least 65% of cellular targets expressing an anti-PR3 antibody.
88. The CAAR of any one of claims 1-86, wherein the CAAR is capable of killing at least 65% of each of at least three cellular targets expressing different anti-PR3 antibodies, wherein each of the at least three different antibodies binds to a different PR3 epitope.
89. The CAAR of claim 87 or 88, wherein the CAAR comprises an amino acid sequence that exhibits at least 85% sequence identity to the sequence shown in any one of SEQ ID NOs: 55, 57, 104, 110 and 111.
90. The CAAR of claim 89, wherein the CAAR comprises a sequence as set forth in any one of SEQ ID NOs: 55, 57, 104, 110, and 111.
91. A polynucleotide comprising a nucleic acid encoding the CAAR of any one of claims 1-90.
92. The polynucleotide of claim 91, wherein the polynucleotide is optimized by splice site elimination.
93. The polynucleotide of claim 91 or claim 92, wherein the polynucleotide is codon optimized for expression in human cells.
94. A polynucleotide according to any one of claims 91-93, wherein the polynucleotide comprises a nucleic acid sequence that exhibits at least 85% sequence identity to the sequence shown in any one of SEQ ID NO:59, 60, 61, 68, 69, 70, 83, 84, 85, 86, 87, 88, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158 or 159.
95. The polynucleotide of claim 94, wherein the polynucleotide comprises a sequence as set forth in any one of SEQ ID NO: 59, 60, 61, 68, 69, 70, 83, 84, 85, 86, 87, 88, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, or 159.
96. A polynucleotide according to any one of claims 91-93, wherein the polynucleotide comprises a nucleic acid sequence that exhibits at least 90% sequence identity with the sequence shown in any one of SEQ ID NO:59, 60, 68, 85, 86, 87, 88, 145, 151 or 152.
97. The polynucleotide of claim 96, wherein the polynucleotide comprises a sequence as set forth in any one of SEQ ID NOs: 59, 60, 68, 85, 86, 87 or 88.
98. A vector comprising the polynucleotide according to any one of claims 91-97.
99. The vector of claim 98, wherein the vector is a viral vector.
100. The vector of claim 99, wherein the viral vector is a retroviral vector (eg, a lentiviral vector).
101. A cell comprising the CAAR of any one of claims 1-100.
102. A cell comprising the polynucleotide of any one of claims 91-97 or the vector of any one of claims 98-100.
103. The cell of claim 101 or claim 102, which is a lymphocyte.
104. The cell of any one of claims 101-103, wherein the cell is a NK cell or a T cell.
105. The cell of any one of claims 101-104, wherein the cell is a T cell, and the T cell is a CD4+ T cell or a CD8+ T cell.
106. The cell of any one of claims 101-105, wherein the cell is a primary cell obtained from a subject.
107. The cell of claim 101 or claim 102, wherein the cell is an induced pluripotent stem cell.
108. The cell of any one of claims 101-105, wherein the cell has been differentiated from an induced pluripotent stem cell.
109. The cell of any one of claims 101-105, wherein the cell is an allogeneic cell.
110. The cell of any one of claims 101-105 and 109, wherein the cell is engineered to be immunoreduced.
111. The cell of any one of claims 101-110, wherein the cell exhibits cytotoxic activity against PR3-reactive B cells.
112. The cell of claim 111, wherein the cytotoxic activity is directed against a plurality of PR3-reactive B cells, wherein the plurality of PR3-reactive B cells are specific for two or more different PR3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) epitopes.
113. The cell of claim 112, wherein the plurality of PR3 reactive B cells are specific for at least 2, 3, 4, 5, 6 or 7 different PR3 ANCA epitopes.
114. The cell of claim 112 or claim 113, wherein the plurality of PR3 reactive B cells are specific for at least 4 different PR3 ANCA epitopes.
115. The cell of any one of claims 112-114, wherein the plurality of PR3 reactive B cells are specific for at least 5 different PR3 ANCA epitopes.
116. The cell of any one of claims 112-115, wherein the plurality of PR3 reactive B cells are specific for at least 6 different PR3 ANCA epitopes.
117. The cell of any one of claims 112-116, wherein the ANCA epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO:90), ANCA3 (PGSHFCGG, SEQ ID NO:91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO:92), ANCA5 (FLNNYDAE, SEQ ID NO:93), ANCA6 (PVPHGTQC, SEQ ID NO:94) and ANCA7 (CFGDSGGP, SEQ ID NO:95).
118. A composition comprising the cells of any one of claims 101-117.
119. The composition of claim 118, further comprising a pharmaceutically acceptable excipient.
120. The composition of claim 118 or claim 119, wherein the composition comprises CD4+ and CD8+ T cells.
121. The composition of claim 120, wherein the ratio of CD4+ to CD8+ T cells is from at or about 1:3 to 3:1, optionally at or about 1:2 to 2:1, optionally at or about 1:
1.
122. The composition of any one of claims 118-121, wherein greater than or greater than about 90%, greater than or greater than about 95%, or greater than or greater than about 98% of the cells in the composition are CD3+ T cells.
123. The composition of any one of claims 118-122, wherein at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition express the CAAR.
124. A composition according to any one of claims 118-123, wherein Among the plurality of cells in the composition expressing the CAAR, less than or less than about 10%, less than or less than about 9%, less than or less than about 8%, less than or less than about 7%, less than or less than about 5%, less than or less than about 4%, less than or less than about 3%, less than or less than about 2%, or less than or less than about 1% of the cells in the plurality of cells exhibit tonic signaling and / or antigen-independent activity or signaling.
125. A method of killing PR3 reactive B cells, the method comprising contacting the PR3 reactive B cells with a cell according to any one of claims 101-117 or a composition according to any one of claims 118-124.
126. The method of claim 125, which is performed in vitro or ex vivo.
127. The method of claim 125, performed in a subject.
128. The method of any one of claims 125-127, wherein the PR3-reactive B cells comprise a plurality of PR3-reactive B cells, wherein the plurality of PR3-reactive B cells are specific for two or more different PR3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) epitopes.
129. The method of claim 128, wherein the plurality of PR3 reactive B cells are specific for 2, 3, 4, 5, 6 or 7 different PR3 ANCA epitopes.
130. The method of claim 128 or claim 129, wherein the plurality of PR3 reactive B cells are specific for at least 4 different PR3 ANCA epitopes.
131. The method of any one of claims 128-130, wherein the plurality of PR3 reactive B cells are specific for at least 5 different PR3 ANCA epitopes.
132. The method of any one of claims 128-131, wherein the plurality of PR3-reactive B cells are specific for at least 6 different PR3 ANCA epitopes.
133. The method of any one of claims 128-132, wherein the ANCA epitope is selected from ANCA2 (AQPHSRPYMAS, SEQ ID NO:90), ANCA3 (PGSHFCGG, SEQ ID NO:91), ANCA4 (VVLGAHNVRTQ, SEQ ID NO:92), ANCA5 (FLNNYDAE, SEQ ID NO:93), ANCA6 (PVPHGTQC, SEQ ID NO:94) and ANCA7 (CFGDSGGP, SEQ ID NO:95).
134. The method according to any one of claims 125-133, wherein: Among a plurality of PR3 reactive B cells, the method results in killing greater than or greater than about 80%, greater than or greater than about 90%, greater than or greater than about 95% of the PR3 reactive B cells, optionally wherein the PR3 reactive B cells are IgG+.
135. A method of treating a disease or disorder in a subject, the method comprising administering to a subject in need of treatment a cell according to any one of claims 101-117 or a composition according to any one of claims 118-124.
136. The method of claim 135, wherein the disease or disorder is an autoimmune disorder.
137. The method of claim 135 and claim 136, wherein the disease or disorder is anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), optionally wherein the AAV is PR3-AAV.
138. The method of any one of claims 135-137, wherein the disease or disorder is selected from granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA).
139. The method of claim 137 or 138, wherein the subject is positive for PR3-ANCA.
140. The method of any one of claims 137-139, wherein the method comprises testing the subject for PR3-ANCA.
141. The method of claim 140, wherein the method comprises verifying that the subject tested positive for PR3-ANCA.
142. The method of any one of claims 137-141, wherein the subject has been treated with a prior therapy (e.g., one or more prior therapies) directed against AAV.
143. The method of claim 142, wherein the subject has failed to achieve remission or has relapsed following treatment with the prior therapy.
144. The method of claim 142 or 143, wherein the prior therapy comprises one or more of glucocorticoids, cyclophosphamide (CYC), rituximab (RTX), plasma exchange, avacopan, methotrexate (MTX), mycophenolate mofetil (MMF), azathioprine (AZA), leflunomide (LEF), belimumab, mepolizumab, and omalizumab.
145. The method of claim 144, wherein the glucocorticoid is one or more of prednisolone, methylprednisolone, prednisone, and dexamethasone.
146. The method of any one of claims 142-145, wherein the prior therapy comprises a remission inducing therapy (e.g., a remission inducing agent).
147. The method of claim 145, wherein the remission induction therapy comprises one or more of rituximab, cyclophosphamide, and glucocorticoids.
148. The method of claim 147, wherein the glucocorticoid is one or more of prednisolone, methylprednisolone, prednisone, and dexamethasone.
149. The method of claim 148, wherein the glucocorticoid is prednisolone.
150. The method of any one of claims 142-149, wherein the prior therapy comprises remission maintenance therapy.
151. The method of claim 150, wherein the remission maintenance therapy comprises one or more of rituximab, methotrexate, azathioprine, mycophenolate mofetil, leflunomide, mepolizumab, and omalizumab.
152. A method of treating a subject suffering from PR3-ANCA vasculitis, the method comprising (i) administering remission induction therapy to the subject; and (ii) administering to the subject the cell according to any one of claims 101-117 or the composition according to any one of claims 118-124.
153. The method of claim 152, wherein the remission induction therapy comprises cyclophosphamide.
154. The method of claim 153, wherein cyclophosphamide is administered to the subject prior to administering the cells or the composition to the subject.
155. The method of claim 153, wherein the subject is administered a course of cyclophosphamide at least 1 week, 2 weeks, 3 weeks, or 4 weeks prior to administering the cells or the composition to the subject.
156. The method of any one of claims 152-155, wherein the remission induction therapy further comprises a glucocorticoid.
157. The method of claim 156, wherein the glucocorticoid is prednisolone.
158. A method of treating a subject suffering from PR3-ANCA vasculitis, the method comprising (i) administering cyclophosphamide to the subject; and (ii) administering to the subject the cell according to any one of claims 101-117 or the composition according to any one of claims 118-124.
159. The method of claim 158, comprising administering cyclophosphamide to the subject prior to administering to the subject the cell of any one of claims 101-117 or the composition of any one of claims 118-124.
160. The method of claim 159, wherein the subject is administered a course of cyclophosphamide at least 1 week, 2 weeks, 3 weeks, or 4 weeks prior to administering the cells or the composition to the subject.
161. The method of claim 158 or 159, wherein the course of cyclophosphamide is administered according to a dosing schedule that has been determined to be sufficient to reduce ANCA titers in patients suffering from PR3-ANCA vasculitis.
162. The method of any one of claims 157-161, wherein cyclophosphamide is administered at an oral dose of 2 mg / kg / day for at least 1 week, 2 weeks, 3 weeks, or 4 weeks prior to administering the cells or the composition to the subject.
163. The method of any one of claims 157-161, wherein cyclophosphamide is administered at an IV dose of 15 mg / kg every 2 weeks for up to 3 doses prior to administering the cells or the composition to the subject.
164. The method of any one of claims 157-163, wherein after administering the cell or the composition to the subject, the subject is not treated with cyclophosphamide.
165. according to the method described in any one of claims 157-164, described method comprises before administering described cell or described composition to described experimenter, administering glucocorticoid to described experimenter.
166. The method of any one of claims 157-165, comprising administering a glucocorticoid to the subject after administering the cell or the composition to the subject.
167. A method of treating a subject suffering from PR3-ANCA vasculitis, the method comprising (i) administering to the subject a preconditioning therapy that has been shown to effectively deplete ANCA, and thereafter; and (ii) administering to the subject the cell according to any one of claims 101-117 or the composition according to any one of claims 118-124.
168. The method of claim 167, wherein the preconditioning therapy comprises cyclophosphamide.
